

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number  
**WO 2005/000806 A2**

- (51) International Patent Classification<sup>7</sup>: **C07D**
- (21) International Application Number:  
PCT/US2004/018340
- (22) International Filing Date: 9 June 2004 (09.06.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/477,468 10 June 2003 (10.06.2003) US
- (71) Applicant (for all designated States except US):  
GEORGETOWN UNIVERSITY [US/US]; 37th and O  
Streets, NW, Washington, DC 20057-1408 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KOZIKOWSKI,**  
**Alan, P.** [US/US]; 222 North Dayton Street, Chicago, IL  
60614 (US). **MUSACHIO, John, L.** [US/US]; 6200 Moss-  
way, Baltimore, MD 21212 (US). **KELLAR, Kenneth,**  
**J.** [US/US]; 7109 Braeburn Place, Bethesda, MD 20817

- (US). **XIAO, Yingxian** [US/US]; 11713 Tifton Drive,  
Potomac, MD 20854 (US). **WEI, Zhi-Liang** [CN/US];  
449 W. 28th Place, 2nd Floor, Chicago, IL 60616-2552  
(US).
- (74) Agents: **GORDON, Dana, M.** et al.; Patent Group, Foley  
Hoag LLP, Seaport World Trade Center West, 155 Seaport  
Boulevard, Boston, MA 02210-2600 (US).
- (81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

- (84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,

[Continued on next page]

(54) Title: LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM

(57) Abstract: One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichillomania.

WO 2005/000806 A2



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

---

***Ligands for Nicotinic Acetylcholine Receptors,  
and Methods of Making and Using Them***

---

5    ***Related Applications***

        This application claims the benefit of the filing date of United States Provisional Patent Application serial number 60/477,468, filed June 10, 2003.

***Background of the Invention***

        The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological  
10    effect via two types of cholinergic receptors; the muscarinic ACh receptors and the nicotinic  
        ACh receptors. As it is well established that muscarinic ACh receptors dominate  
        quantitatively over nicotinic ACh receptors in the brain area important to memory and  
        cognition, much research aimed at the development of agents for the treatment of memory  
        related disorders have focused on the synthesis of muscarinic ACh receptor modulators.  
15    Recently, however, an interest in the development of nicotinic ACh receptor modulators has  
        emerged. Several diseases are associated with degeneration of the cholinergic system i.e.  
        senile dementia of the Alzheimer type, vascular dementia and cognitive impairment due to  
        the organic brain damage disease related directly to alcoholism. Indeed several CNS  
        disorders can be attributed to a cholinergic deficiency, a dopaminergic deficiency, an  
20    adrenergic deficiency or a serotonergic deficiency. Alzheimer's disease is characterised by a  
        profound loss of memory and cognitive functions caused by a severe depletion of  
        cholinergic neurons, i.e. neurons that release acetylcholine. A reduction in the number of  
        nicotinic ACh receptors are also observed with the progression of Alzheimer's disease. It is  
        believed that the neurons in the cortex that die with the progression of Alzheimer's disease  
25    do so because of lack of stimulation of the nicotinic ACh receptors. It is predicted that  
        treatment of Alzheimer patients with nicotinic ACh receptor modulators will not only  
        improve the memory of patients but in addition act to keep these neurons alive. Smoking  
        actually seems to protect individuals against neurodegeneration and compounds behaving  
        on these receptor may very likely have a generally neuroprotective effect.

30          However degeneration of the cholinergic system is not limited to individuals  
        suffering from i.e. Alzheimers disease but is also seen in healthy aged adults and rats.  
        Therefore it is suggested that the cholinergic system is involved and partly responsible for

the memory disturbances seen in aged animals and humans. Nicotine receptor modulator may therefore be useful in the treatment of Alzheimer's disease, memory loss, memory dysfunction, AIDS-dementia, senile dementia or neurodegenerative disorders.

Parkinsons disease appears to involve degeneration of dopaminergic neurons. One  
5 symptom of the disease has been observed to be loss of nicotinic receptors associated with the dopaminergic neurons and possibly interfering with the process of release of dopamine. As sustained nicotine administration increases the number of receptors present, administration of nicotine receptor modulators may ameliorate the symptoms of Parkinson's disease. Other condition or disorders or disease ascribed to deficiencies in the  
10 dopaminergic system is: drug addiction, depression, obesity and narcolepsy.

Tourette's syndrome is a neuropsychiatric disorder involving a range of neurological and behavioral symptoms. It is believed that neurotransmitter dysfunction is involved though the pathophysiology is still unknown and that nicotine will be beneficial in the treatment of the disease (Devor et. al. The Lancet, vol. 8670 p. 1046, 1989).

15 Schizophrenia is a severe psychiatric illness. Neuroleptic compounds has been used in the treatment of the disease, the effect of the compounds is believed to be interaction in the dopaminergic system. Nicotine is proposed to be effective in the treatment of schizophrenia (Merriam et. al. Psychiatr. annals, Vol. 23, p. 171-178, 1993 and Adler et. al. Biol. Psychiatry, Vol. 32, p. 607-616, 1992.)

20 Nicotine has been reported to have an effect on neurotransmitter release in several systems. Release of acetylcholine and dopamine by neurons upon administration of nicotine has been reported (J. Neurochem. vol. 43, 1593-1598, 1984) and release of norepinephrine by Hall et. al. (Biochem. Pharmacol. vol. 21, 1829-1838, 1972) Release of serotonin by Hery et. al. (Arch. Int. Pharmacodyn. Ther. vol. 296. p. 91-97, 1977). Release  
25 of glutamate by Toth et. al (Neurochem. Res. vol. 17, p. 265-271, 1992).

The serotonin system and dysfunction's of the serotonergic system is believed to be involved in diseases or conditions or disorders like: anxiety, depression, eating disorders, obsessive compulsive disorder, panic disorders, chemical substance abuse, alcoholism, pain, memory deficits and anxiety, pseudodementia, Ganser's syndrome, migraine pain, bulimia,  
30 obesity, pre-menstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation,

erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichotillomania.

Nicotine improves concentration and task performance. Therefore compounds exhibiting nicotine receptor modulating properties will be likely to be useful compounds in the treatment of learning deficit, cognition deficit, attention deficit, attention deficit  
5 hyperactivity disorder and dyslexia.

Tobacco use and especially cigarette smoking is recognised as a serious health problem. However nicotine withdrawal symptoms associated with smoking cessation makes it difficult to break this habit. Withdrawal symptoms include anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and  
10 weight gain. Nicotine itself has shown to ease the withdrawal symptoms.

Withdrawal from addictive substances, i.e. opiates, benzodiazepines, ethanol, tobacco or nicotine, is in general a traumatic experience characterized by anxiety and frustration. Nicotine has been found to be effective in reducing anger, irritability, frustration and feelings of tension without causing general response depression, drowsiness  
15 or sedation and compounds having same characteristics as nicotine is likely to have same effects.

Mild to moderate pain is normally treatable with NSAID's (non-steroidal anti-inflammatory drugs) while opiates are used preferentially for moderate to severe pain. The opiates have some well-known side-effects, including chemical dependence and abuse  
20 potential as well as a depressive effect on the respiratory and gastrointestinal system. There exists therefore a strong need for analgesic compounds that do not exhibit these side effects and which can relieve mild, moderate and severe pain of acute, chronic or recurrent character as well as migraine pain and postoperative pain, phantom limb pain.

Epibatidine, a compound isolated from the skin of a poison frog, is a very potent  
25 analgesic with an approximate potency of 500 times that of morphine. The analgesic effect is not affected by naloxone, which is an indication of a negligible affinity for the opiate receptors. Epibatidine is an nicotinic cholinergic receptor agonist and it is therefore very likely, that compounds possessing this receptor modulating character will also show a strong analgesic response. It is well known that nicotine has an effect on appetite and it is  
30 predicted, that modulators at the nicotine ACh receptor may be useful as appetite suppressants in the treatment of obesity and eating disorders.

In addition to epibatidine, various heterocyclic 2-pyrrolidinyloxy-substituted compounds with analgesic and hypotensive activities have been disclosed by Scheffler et al. (U.S. Pat. No. 4,643,995) and Tomioka et al. (Chem. Pharm. Bull, 38:2133-5, 1990).

Certain other 2-pyridyloxy-substituted compounds are disclosed inter alia by Engel  
5 et al. in U.S. Pat. No. 4,946,836 as having analgesic activity.

Various other compounds having a pyrrolidine or azetidine moiety substituted at the 3-position with a heterocycloxy group have also been disclosed (cf. U.S. Pat. No. 4,592,866 to A. D. Cale; U.S. Pat. No. 4,705,853 to A. D. Cale; U.S. Pat. No. 4,956,359 to Taylor et al.; and U.S. Pat. No. 5,037,841 to Schoehe et al. and European patent application  
10 EP296560A2, to Sugimoto et al.).


The cholinergic receptors play an important role in the functioning of muscles, organs and generally in the central nervous system. There are also complex interactions between cholinergic receptors and the function of receptors of other neurotransmitters such as dopamine, serotonin and noradrenaline.

15 It is likely that nicotine receptor modulator compounds can be effective in preventing or treating conditions or disorders or diseases like: inflammation, inflammatory skin conditions, Chron's disease, inflammatory bowel disease, ulcerative colitis, diarrhoea, neurodegeneration, peripheral neuropathy, amyotrophic lateral sclerosis, nociception, endocrine disorders, thyrotoxicosis, pheochromocytoma, hypertension, arrhythmias, mania,  
20 manic depression, Huntington's disease, jetlag.

The compounds of the present invention are nicotine receptor modulators and have the potential to exhibit nicotinic pharmacology, preferentially without the side effects associated with nicotine itself. Additionally, the compounds are expected to have the potential as enhancers of neurotransmitter secretion and suppress symptoms associated with  
25 a low activity of neurotransmitters.

**Summary of the Invention**

In part, the present invention relates to a compound of formula I:



I

5 wherein, independently for each occurrence,


a is 1 or 2;

b is 1, 2, or 3;

R is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl, or aralkyl, optionally substituted with one or more halide, hydroxy, alkoxy, amino, nitro, or -OR<sub>2</sub> group, wherein

10 R<sub>2</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl, or aralkyl;

R<sub>1</sub> is H, halide, hydroxy, alkoxy, amino, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl, aralkyl, or any two R<sub>1</sub> can form a fused ring; or



R is of formula Ia:  $\text{---}(\text{CH}_2)_n\text{---}$  N (bicyclic system with bridge 'a' and substituent '(R<sub>1</sub>)<sub>b</sub>'), wherein, independently for each occurrence,

n is an integer from 1 to 6 inclusively;

15 a is 1 or 2;

b is 1, 2, or 3; and

R<sub>1</sub> is H, halide, hydroxy, alkoxy, amino, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl, aralkyl, or any two R<sub>1</sub> can form a fused ring.

In a further embodiment, the present invention relates to a compound of formula I  
20 and the attendant definitions, wherein a is 1.

In a further embodiment, the present invention relates to a compound of formula I and the attendant definitions, wherein  $R_1$  is H and b is 3.

In a further embodiment, the present invention relates to a compound of formula I and the attendant definitions, wherein R is Ia and the attendant definitions.

5 In a further embodiment, the present invention relates to a compound of formula I and the attendant definitions, wherein a is 1,  $R_1$  is H, b is 3, and R is  $-C_2H_5Cl$ .


In a further embodiment, the present invention relates to a compound of formula I and the attendant definitions, wherein a is 1,  $R_1$  is H, b is 3, and R is  $-C_3H_5O-3$ -pyridinyl.

10 In a further embodiment, the present invention relates to a compound of formula I and the attendant definitions, wherein a is 1,  $R_1$  is H, b is 3, and R is Ia, wherein a is 1,  $R_1$  is H, b is 3, and n is 2.

In a further embodiment, the present invention relates to a compound of formula I and the attendant definitions, wherein a is 1,  $R_1$  is H, b is 3, and R is Ia, wherein a is 1,  $R_1$  is H, b is 3, and n is 4.

15 In a further embodiment, the present invention relates to a compound of formula I and the attendant definitions, wherein a is 1,  $R_1$  is H, b is 3, and R is Ia, wherein a is 1,  $R_1$  is H, b is 3, and n is 5.

In another embodiment the present invention relates to a compound of formula II:



II

wherein, independently for each occurrence,

R is H,  $C_1-C_6$  alkyl,  $C_2-C_8$  alkenyl,  $C_2-C_8$  alkenyl, aryl, heteroaryl, or aralkyl, optionally substituted with one or more halide, hydroxy, alkoxy, amino, or nitro groups;




$R_{1a}$ ,  $R_{1e}$ ,  $R_{2a}$ ,  $R_{2e}$ ,  $R_{3a}$ ,  $R_{3e}$ ,  $R_{4a}$  and  $R_{4e}$  are selected from the group consisting of H, hydroxy, amino, halide, aryl, alkoxy, and heteroaryl groups, wherein the aryl and heteroaryl groups are optionally substituted with one or more halide, alkyl, alkenyl, or alkynyl groups; or

5 any geminal  $R_{1a}$ ,  $R_{1e}$ ,  $R_{2a}$ ,  $R_{2e}$ ,  $R_{3a}$ ,  $R_{3e}$ ,  $R_{4a}$  and  $R_{4e}$  groups may form a monocyclic or bicyclic ring, or =O; or

any adjacent  $R_{1a}$ ,  $R_{1e}$ ,  $R_{2a}$ ,  $R_{2e}$ ,  $R_{3a}$ ,  $R_{3e}$ ,  $R_{4a}$  and  $R_{4e}$  groups may form a monocyclic or bicyclic ring; and

10 providing that at least one of  $R_{1a}$  or  $R_{1e}$  is hydroxy or heteroaryl, and if  $R_{1a}$  or  $R_{1e}$  is hydroxy then  $R_{2a}$  or  $R_{2e}$  is heteroaryl, and if  $R_{1a}$  or  $R_{1e}$  is heteroaryl then at least one  $R_{2a}$ ,  $R_{2e}$ ,  $R_{3a}$ ,  $R_{3e}$ ,  $R_{4a}$  or  $R_{4e}$  is not H;

or



R is of formula IIa:

wherein, independently for each occurrence,

15  $R_{1a}$ ,  $R_{1e}$ ,  $R_{2a}$ ,  $R_{2e}$ ,  $R_{3a}$ ,  $R_{3e}$ ,  $R_{4a}$  and  $R_{4e}$  are selected from the group consisting of H, hydroxy, amino, halide, aryl, alkoxy, and heteroaryl groups, wherein the aryl and heteroaryl groups are optionally substituted with one or more halide, alkyl, alkenyl, or alkynyl groups; and

n is an integer from 1 to 9 inclusively.

20 In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein  $R_{1a}$  is OH.

In a further embodiment, the present invention relates to a compound of formula II

and the attendant definitions, wherein R<sub>1e</sub> is OH.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>1a</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II  
5 and the attendant definitions, wherein R<sub>1e</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>2a</sub> is OH.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>2e</sub> is OH.

10 In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>2a</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>2b</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II  
15 and the attendant definitions, wherein R<sub>1e</sub> is F.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>1a</sub> is F.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>2a</sub> is F.

20 In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>2e</sub> is F.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1a</sub> is OH, and R<sub>2a</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II  
25 and the attendant definitions, wherein R is H, R<sub>1e</sub> is OH, and R<sub>2a</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>2e</sub> is OH.

In a further embodiment, the present invention relates to a compound of formula II

and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>2a</sub> is OH.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>3a</sub> is OH.

In a further embodiment, the present invention relates to a compound of formula II  
5 and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>4a</sub> is OH.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>3e</sub> is OH.


In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>4e</sub> is OH.

10 In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>3e</sub> is F.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>4e</sub> is F.


In a further embodiment, the present invention relates to a compound of formula II

15 and the attendant definitions, wherein R is H, and R<sub>1a</sub> and R<sub>1e</sub> form




In a further embodiment, the present invention relates to a compound of formula II

and the attendant definitions, wherein R is H, and R<sub>1e</sub> and R<sub>2e</sub> form




In a further embodiment, the present invention relates to a compound of formula II

and the attendant definitions, wherein R is H, and R<sub>1a</sub> and R<sub>1e</sub> form



20 In a further embodiment, the present invention relates to a compound of formula II

and the attendant definitions, wherein R is H, and R<sub>1e</sub> and R<sub>2e</sub> form




In a further embodiment, the present invention relates to a compound of formula II

and the attendant definitions, wherein R is H and R<sub>1e</sub> is 2-(6-hydroxy-1-hexynyl)-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>3a</sub> and R<sub>3e</sub> form =O.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>4a</sub> and R<sub>4e</sub> form =O.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R is H, R<sub>1e</sub> is 2-chloro-5-pyridinyl, and R<sub>4a</sub> and R<sub>4e</sub>



In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>1e</sub> is 2-chloro-5-pyridinyl and R is IIa and the attendant definitions, wherein n is 5, and R<sub>1e</sub> is 2-chloro-5-pyridinyl.


In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>1e</sub> is 2-chloro-5-pyridinyl and R is IIa and the attendant definitions, wherein n is 2, and R<sub>1e</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>1e</sub> is 2-chloropyridin-5-yl and R is IIa and the attendant definitions, wherein n is 9, and R<sub>1e</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>1e</sub> is 2-chloro-5-pyridinyl and R is IIa and the attendant definitions, wherein n is 1, and R<sub>1e</sub> is 2-chloro-5-pyridinyl.

In a further embodiment, the present invention relates to a compound of formula II and the attendant definitions, wherein R<sub>2e</sub> is 2-chloro-5-pyridinyl and R is IIa and the attendant definitions, wherein n is 1, and R<sub>1e</sub> is 2-chloro-5-pyridinyl.

In another embodiment, the present invention relates to compound of formula **III**:



**III**

5 wherein, independently for each occurrence,

L is O, S, or NR;

Het is a heterocyclic; and

R is H, halide, amino, nitro, hydroxy, alkoxy, or an optionally substituted C<sub>1</sub>-C<sub>6</sub> alky, C<sub>2</sub>-C<sub>6</sub> alkenyl, or C<sub>2</sub>-C<sub>10</sub> alkynyl, where the substituents are selected from the group  
10 consisting of hydroxy, halide, amino, nitro, and alkoxy.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein Het is 1-methyl-2-pyrrolidinyl.

15 In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein Het is 2-azetidiny.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein R is H.

20 In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein R is Br.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein R is an alkynyl group.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein R is an hydroxy substituted alkynyl group.

25 In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 1-methyl-2-pyrrolidinyl, and R is H.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 1-methyl-2-pyrrolidinyl, and R is Br.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 1-methyl-2-pyrrolidinyl, and R is -

5 CCH.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 1-methyl-2-pyrrolidinyl, and R is -CCCH<sub>2</sub>OH.

10 In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 1-methyl-2-pyrrolidinyl, and R is -CC(CH<sub>2</sub>)<sub>4</sub>OH.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 1-methyl-2-pyrrolidinyl, and R is - (CH<sub>2</sub>)<sub>6</sub>OH.


15 In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 1-methyl-2-pyrrolidinyl, and R is -CC(CH<sub>2</sub>)<sub>8</sub>OH.

In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 2-azetidiny, and R is H.

20 In a further embodiment, the present invention relates to a compound of formula **III** and the attendant definitions, wherein L is O, Het is 2-azetidiny, and R is -CC(CH<sub>2</sub>)<sub>4</sub>OH.

In another embodiment, the present invention relates to a pharmaceutical composition comprising a compound of formula **I**, **II**, or **III** and a pharmaceutically acceptable excipient.

25 In cases in which the compounds of formula **I**, **II**, or **III** have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention. In cases wherein the compounds may exist in tautomeric forms, such as keto-

enol tautomers, such as , each tautomeric form is contemplated as being included within this invention, whether existing in equilibrium or locked in one form by

appropriate substitution with R'. The meaning of any substituent at any one occurrence is independent of its meaning, or any other substituent's meaning, at any other occurrence.

Also included in the nicotine AChR ligand compounds of the present invention are prodrugs of the compounds of formula I, II, or III. Prodrugs are considered to be any  
5 covalently bonded carriers which release the active parent drug *in vivo*.

The compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

10 It will be appreciated by those skilled in the art that the compounds of the present invention contain several chiral centers and that such compounds exist in the form of isomers (i.e. enantiomers). The invention includes all such isomers and any mixtures thereof including racemic mixtures.

Racemic forms can be resolved into the optical antipodes by known methods, for  
15 example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or l-(tartrates,  
20 mandelates, or camphorsulphonate) salts for example. The compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the  
25 present invention with an optically active chloroformate or the like.

Additional methods for the resolution of optical isomers, known to those skilled in the art may be used, and will be apparent to the average worker skilled in the art. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

30 Optical active compounds can also be prepared from optical active starting materials.

In another embodiment, the present invention relates to a compound of formula I, II, or III, wherein the compound has an  $IC_{50}$  less than 1  $\mu M$  in an assay based on a mammalian nicotine ACh receptor. In a further embodiment, the compound of formula I, II, or III has an  $IC_{50}$  less than 100 nM in an assay based on a mammalian nicotine ACh receptor. In a further embodiment, the compound of formula I, II, or III has an  $IC_{50}$  less than 10 nM in an assay based on a mammalian nicotine ACh receptor. In a further embodiment, the compound of formula I, II, or III has an  $IC_{50}$  less than 1 nM in an assay based on a mammalian nicotine ACh receptor.

In another embodiment, the present invention relates to a compound of formula I, II, or III, wherein the compound has an  $EC_{50}$  less than 1  $\mu M$ . In a further embodiment the compound has an  $EC_{50}$  less than 100 nM in an assay based on a mammalian nicotine ACh receptor. In a further embodiment, the compound of formula I, II, or III, wherein the compound has an  $EC_{50}$  less than 10 nM in an assay based on a mammalian nicotine ACh receptor.

In another embodiment, the present invention relates to a compound of formula I, II, or III, wherein the compound is a single stereoisomer.

In accordance with the present invention, a compound of the present invention may be prepared as pharmaceutical compositions that are particularly useful for the treatment of neurodegenerative diseases or addictive disorders. Such compositions comprise a compound of the present invention with pharmaceutically acceptable carriers and/or excipients.

For example, these compositions may be prepared as medicines to be administered orally, parenterally, rectally, transdermally, buccally, or nasally. Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets of powder for reconstitution, hard or gelatin capsules, sub-lingual tablets, syrups and suspensions. Suitable forms for parenteral administration include an aqueous or non-aqueous solution or emulsion, while for rectal administration suitable forms include suppositories with hydrophilic or hydrophobic vehicles. For topical application the invention provides ointments or aerosol formulations known in the art; for transdermal delivery there are provided suitable delivery systems as known in the art. For nasal delivery there are provided suitable aerosol delivery systems known in the art.



In another aspect of the present invention, the pharmaceutical compositions of the present invention may be used in the manufacture of a medicament to treat neurodegenerative or addictive disorders. In certain embodiments, the present invention is directed to a method for formulating compositions of the present invention in a pharmaceutically acceptable carrier.

In certain embodiments, the pharmaceutical compositions are formulated as a tablet, pill capsule or other appropriate ingestible formulation, to provide a therapeutic dose in 10 tablets or fewer. In another example, a therapeutic dose is provided in 50, 40, 30, 20, 15, 10, 5 or 3 tablets.

In another aspect, the present invention also provides for kits containing at least one dose of a subject composition, and often many doses, and other materials for a treatment regimen. For example, in one embodiment, a kit of the present invention contains sufficient subject composition for from five to thirty days and optionally equipment and supplies necessary to measure one or more indices relevant to the treatment regimen. In another embodiment, kits of the present invention contain all the materials and supplies, including subject compositions, for carrying out any methods of the present invention. In still another embodiment, kits of the present invention, as described above, additionally include instructions for the use and administration of the subject compositions.

The dosage may be selected to assuage the disorder in a subject in such a way as to provide at least partial relief if not complete relief. The skilled artisan may identify this amount as provided herein as well as by using other methods known in the art.

In another embodiment, the present invention relates to a method of modulating a nicotine ACh receptor in a mammal comprising administering to the mammal a compound of formula I, II, or III. In a further embodiment, the mammal is a primate, equine, canine, or feline. In a further embodiment, the mammal is a human.

In another embodiment, the present invention relates to a method of modulating a nicotine ACh receptor in a mammal comprising administering to the mammal a compound of formula I, II, or III, wherein the compound is administered orally. In a further embodiment, the compound is administered intravenously, sublingually, ocularly, transdermally, rectally, vaginally, topically, intramuscularly, subcutaneously, buccally, or nasally.

In another embodiment, the present invention relates to a method of treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichotillomania comprising administering a therapeutically effective amount of a compound of formula I, II, or III. In a further embodiment, the mammal is a primate, equine, canine, or feline. In a further embodiment, the mammal is a human. In a further embodiment, the compound is administered orally, intravenously, sublingually, ocularly, transdermally, rectally, vaginally, topically, intramuscularly, subcutaneously, buccally, or nasally.

As explained herein in greater detail, the invention will readily enable the design and implementation of trials in warm-blooded animals, including humans and mammals, necessary for easily determining or tailoring the form and dose for any composition of the present invention.

These embodiments of the present invention, other embodiments, and their features and characteristics, will be apparent from the description, drawings and claims that follow.

#### ***Brief Description of the Figures***

Figure 1 depicts the structure of a neuronal nicotinic acetylcholine receptor (nAChR).

Figure 2 depicts the chemical structures of (-)-nicotine, cytisine, (-)-epibatidine, and compound A-84543.

Figure 3 depicts the functionalization of the alicyclic skeleton of epibatidine.

Figure 4 depicts the synthesis of conformationally constrained epibatidine analogs.

Figure 5 depicts the limited rotational movement of the constrained epibatidine analogs.

## *Detailed Description of the Invention*

### Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

5       The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

      The term "ED<sub>50</sub>" means the dose of a drug which produces 50% of its maximum response or effect. Alternatively, the dose which produces a pre-determined response in  
10   50% of test subjects or preparations.

      The term "LD<sub>50</sub>" means the dose of a drug which is lethal in 50% of test subjects.

      The term "therapeutic index" refers to the therapeutic index of a drug defined as LD<sub>50</sub>/ED<sub>50</sub>.

      The term "structure-activity relationship (SAR)" refers to the way in which altering  
15   the molecular structure of drugs alters their interaction with a receptor, enzyme, etc.

      The term "agonist" refers to a compound that mimics the action of natural transmitter or, when the natural transmitter is not known, causes changes at the receptor complex in the absence of other receptor ligands.

      The term "antagonist" refers to a compound that binds to a receptor site, but does  
20   not cause any physiological changes unless another receptor ligand is present.

      The term "inverse agonist" refers to a compound that binds to a constitutively active receptor site and reduces its physiological function.

      The term "competitive antagonist" refers to a compound that binds to a receptor site; its effects can be overcome by increased concentration of the agonist.

25       The term "partial agonist" refers to a compound that binds to a receptor site but does not produce the maximal effect regardless of its concentration.

      The term "ligand" refers to a compound that binds at the receptor site.

      The term "heteroatom" as used herein means an atom of any element other than

carbon or hydrogen. Preferred heteroatoms are boron, nitrogen, oxygen, phosphorus, sulfur and selenium.

The term "alkyl" refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In preferred  
5 embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C<sub>1</sub>-C<sub>30</sub> for straight chain, C<sub>3</sub>-C<sub>30</sub> for branched chain), and more preferably 20 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.

10 Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Preferred alkyl groups are lower alkyls. In preferred embodiments, a substituent designated herein as alkyl is a lower alkyl.

15 The term "aralkyl", as used herein, refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).

The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

20 The term "aryl" as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, naphthalene, anthracene, pyrene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles" or  
25 "heteroaromatics." The aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, -CF<sub>3</sub>, -CN, or the like.  
30 The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings")

wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.

The terms *ortho*, *meta* and *para* apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and *ortho*-dimethylbenzene are  
5 synonymous.


The terms "heterocyclyl" or "heterocyclic group" refer to 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can also be polycycles. Heterocyclyl groups include, for example, azetidine, azepine, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene,  
10 xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane,  
15 thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone,  
20 aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF<sub>3</sub>, -CN, or the like.

The terms "polycyclyl" or "polycyclic group" refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are  
25 joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF<sub>3</sub>, -CN, or  
30 the like.

The term "carbocycle", as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.


As used herein, the term "nitro" means  $\text{-NO}_2$ ; the term "halogen" designates  $\text{-F}$ ,  $\text{-Cl}$ ,  $\text{-Br}$  or  $\text{-I}$ ; the term "sulfhydryl" means  $\text{-SH}$ ; the term "hydroxyl" means  $\text{-OH}$ ; and the term  
 5 "sulfonyl" means  $\text{-SO}_2\text{-}$ .

The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula:




wherein  $\text{R}_9$ ,  $\text{R}_{10}$  and  $\text{R}'_{10}$  each independently represent a group permitted by the rules of  
 10 valence.

The term "acylamino" is art-recognized and refers to a moiety that can be represented by the general formula:



wherein  $\text{R}_9$  is as defined above, and  $\text{R}'_{11}$  represents a hydrogen, an alkyl, an alkenyl or  
 15  $\text{-(CH}_2\text{)}_m\text{-R}_8$ , where  $m$  and  $\text{R}_8$  are as defined above.


The term "amido" is art recognized as an amino-substituted carbonyl and includes a moiety that can be represented by the general formula:



wherein  $\text{R}_9$ ,  $\text{R}_{10}$  are as defined above. Preferred embodiments of the amide will not  
 20 include imides which may be unstable.

The term "alkylthio" refers to an alkyl group, as defined above, having a sulfur radical attached thereto. In preferred embodiments, the "alkylthio" moiety is represented by one of -S-alkyl, -S-alkenyl, -S-alkynyl, and -S-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, wherein m and R<sub>8</sub> are defined above. Representative alkylthio groups include methylthio, ethyl thio, and the like.

- 5        The term "carbonyl" is art recognized and includes such moieties as can be represented by the general formula:



- wherein X is a bond or represents an oxygen or a sulfur, and R<sub>11</sub> represents a hydrogen, an alkyl, an alkenyl, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub> or a pharmaceutically acceptable salt, R'<sub>11</sub> represents a  
 10    hydrogen, an alkyl, an alkenyl or -(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, where m and R<sub>8</sub> are as defined above. Where X is an oxygen and R<sub>11</sub> or R'<sub>11</sub> is not hydrogen, the formula represents an "ester". Where X is an oxygen, and R<sub>11</sub> is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R<sub>11</sub> is a hydrogen, the formula represents a "carboxylic acid". Where X is an oxygen, and R'<sub>11</sub> is hydrogen, the formula represents a  
 15    "formate". In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a "thiolcarbonyl" group. Where X is a sulfur and R<sub>11</sub> or R'<sub>11</sub> is not hydrogen, the formula represents a "thiolester." Where X is a sulfur and R<sub>11</sub> is hydrogen, the formula represents a "thiolcarboxylic acid." Where X is a sulfur and R'<sub>11</sub> is hydrogen, the formula represents a "thiolformate." On the other hand, where X is a bond, and R<sub>11</sub> is  
 20    not hydrogen, the above formula represents a "ketone" group. Where X is a bond, and R<sub>11</sub> is hydrogen, the above formula represents an "aldehyde" group.

- The terms "alkoxyl" or "alkoxy" as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An "ether" is two hydrocarbons  
 25    covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(CH<sub>2</sub>)<sub>m</sub>-R<sub>8</sub>, where m and R<sub>8</sub> are described above.

The abbreviations Me, Et, Ph, Tf, Nf, Ts, Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, *p*-toluenesulfonyl and methanesulfonyl, respectively. A more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the  
5 *Journal of Organic Chemistry*; this list is typically presented in a table entitled Standard List of Abbreviations. The abbreviations contained in said list, and all abbreviations utilized by organic chemists of ordinary skill in the art are hereby incorporated by reference.

Analogous substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls,  
10 iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or alkynyls.

As used herein, the definition of each expression, e.g. alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

It will be understood that "substitution" or "substituted with" includes the implicit  
15 proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

As used herein, the term "substituted" is contemplated to include all permissible  
20 substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this  
25 invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.

The phrase "protecting group" as used herein means temporary substituents which  
30 protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of



alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. *Protective Groups in Organic Synthesis*, 2<sup>nd</sup> ed.; Wiley: New York, 1991).


Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including  
5 *cis*- and *trans*-isomers, *R*- and *S*-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in  
10 this invention.

If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, it may be isolated using chiral chromatography methods, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure  
15 desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.

Contemplated equivalents of the compounds described above include compounds which otherwise correspond thereto, and which have the same general properties thereof (e.g., functioning as analgesics), wherein one or more simple variations of substituents are made which do not adversely affect the efficacy of the compound in binding to opioid receptors. In general, the compounds of the present invention may be prepared by the  
20 methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are in themselves known, but are not mentioned here.


For purposes of this invention, the chemical elements are identified in accordance  
30 with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.

Discussion of Selected Preferred Embodiments




5

It has been shown that C-5 position of the pyridyl moiety of A-84543 (8) could tolerate sterically bulky substituents without losing the binding affinity at  $\alpha 4\beta 2$  nAChR. We investigated the effects of the C-5 substituents of the pyridine on the binding affinity and subtype-selectivity at neuronal nicotinic acetylcholine receptors caused by the steric factor as well as the hydrophathy profile of the introduced group. In the nicotinic series, introduction of an ethynyl substituent at the C-5 position of the pyridyl ring lead to SIB-1508Y (4) with altered subtype selectivity for neuronal nAChRs. Thus, a series of 5-alkynyl substituted A-84543 analogues 11-17 were prepared in good yields from 5-bromo derivative 10 by Pd-C catalyzed Sonogashira reaction in aqueous system (Scheme 1). The intermediate 10 was readily obtained by treatment of 3,5-dibromopyridine with (S)-1-methyl-2-pyrrolidinylmethanol (9) in the presence of sodium hydride. The 5-ethynyl derivative 19 was prepared by treatment 12 with NaH. Catalytic hydrogenation of 10 and 16 on Pd-C provided 8 and 19, respectively.

Scheme 1.<sup>a</sup>


<sup>a</sup> Reagents: (i) NaH, DMF, then 3,5-dibromopyridine, room temperature, 70%; (ii) 10% Pd-C, EtOH, H<sub>2</sub> (1 atm), 99%; (iii) Alkyne, 10% Pd-C (cat.), CuI (cat.), K<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, reflux, 72 h, 55-95%; (iv) NaH (cat.), toluene, 120 °C, 1 h, 99%; (v) 10% Pd-C, EtOAc, H<sub>2</sub> (1 atm), 99%.

5-(6-Hydroxy-1-hexynyl) derivative 26 and *N*-demethyl analogue of 16 were synthesized as shown in Scheme 2. Treatment of the alcohols 20 and 21 with 3-bromo-5-hydroxypyridine under Mitsunobu conditions provided the corresponding 3-pyridyl ethers 22 and 23, which were coupled with 5-hexyn-1-ol under the Pd-C catalyzed Sonogashira reaction protocol to afford the corresponding 24 and 25 in good yield. Removal of the Boc protection groups in 24 and 25 provided 26 and 27, respectively.


Scheme 2.<sup>a</sup>

<sup>a</sup> Reagents: (i) 3-Brom-5-hydroxypyridine, PPh<sub>3</sub>, DEAD, THF, room temperature, 81-85%; (ii) a) 5-Hexyn-1-ol, 10% Pd-C (cat.), CuI (cat.), K<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, reflux, 72 h, 83-95%; b) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, 85-93%.

Two epibatidine analogues 31 and 34 were prepared as shown in Schemes 3 and 4, respectively. Reductive Heck reaction of the olefin 28 with 3,5-dibromopyridine provided 29, which was coupled with 6-[(*tert*-butyldimethylsilyl)oxy]-1-hexyne under the catalysis with Pd(PPh<sub>3</sub>)Cl<sub>2</sub> and CuI to give 30. Removal of the TBS and Boc protection groups together with trifluoroacetic acid provided 5-(6-hydroxy-1-hexynyl) substituted dechloroepibatidine analogue 31 (Scheme 3). 6-(6-Hydroxy-1-hexynyl) substituted epibatidine analogue 34 were prepared from 32 in a similar manner (Scheme 4).


Scheme 3<sup>a</sup>

<sup>a</sup> Reagents: (i) 3,5-Dibromopyridine, Pd(PPh<sub>3</sub>)<sub>4</sub> (cat.), piperidine, HCO<sub>2</sub>H, DMF, 80 °C, 72 h, 61%; (ii) a) 6-[(*tert*-Butyldimethylsilyl)oxy]-1-hexyne, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, Bu<sub>4</sub>Nl, Et<sub>3</sub>N, DMF, reflux, 48 h, 93%; b) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, 90%.


Scheme 4<sup>a</sup>

<sup>a</sup> Reagents: (i) 6-[(*tert*-Butyldimethylsilyl)oxy]-1-hexyne, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, Bu<sub>4</sub>Nl, Et<sub>3</sub>N, DMF, room temperature, 24 h; then 60 °C, 24 h, 94%; (ii) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, 81%.

Three fluorine-containing 3-pyridyl ether analogues **36**, **41**, and **42** were also prepared, in particular, with the expectation that they could serve for PET imaging purposes if appropriately labeled with  $^{18}\text{F}$ . 5-(6-Fluoro-1-hexynyl) derivative **36** was prepared from the alcohol **16** by treatment with iodine in the presence of  $\text{PPh}_3$  and imidazole, followed by silver fluoride (Scheme 5). Tosylation of the alcohols **24** and **25** provided the corresponding tosylates **37** and **38**. Treatment of **37** and **38** with tetrabutylammonium fluoride followed by trifluoroacetic acid gave **41** and **42**, respectively, in good yields (Scheme 6).

Scheme 5<sup>a</sup>

<sup>a</sup> Reagents: (i)  $\text{I}_2$ ,  $\text{PPh}_3$ , imidazole,  $\text{CH}_2\text{Cl}_2$ , 92%; (ii)  $\text{AgF}$ , acetonitrile, room temperature, 10 h, 57%.


Scheme 6<sup>a</sup>

<sup>a</sup> Reagents: (i)  $p\text{-TsCl}$ ,  $\text{Et}_3\text{N}$ , DMAP (cat.),  $\text{CH}_2\text{Cl}_2$ , 75-82%; (ii) a) Tetrabutylammonium fluoride (1 M in THF), room temperature, 10-15 h, 97-100%; b)  $\text{CF}_3\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{Cl}_2$ , 87-93%.

In order to assess the steric and hydrophobic effects of the C-5 substituents of the pyridine on the binding affinity and subtype-selectivity at neuronal nicotinic acetylcholine receptors. A series of A-84543 analogues **10**–**19** were evaluated by their binding assays at

the six heterologously expressed nAChR subtypes ( $\alpha 2\beta 2$ ,  $\alpha 2\beta 4$ ,  $\alpha 3\beta 2$ ,  $\alpha 3\beta 4$ ,  $\alpha 4\beta 2$ , and  $\alpha 4\beta 4$ ) and at receptors in rat forebrain. The results are summarized in Table 1. The binding affinity ratios for a ligand, calculated from its affinities at an  $\alpha$  subunit paired with either the  $\beta 2$  subunit or the  $\beta 4$  subunit, represents a measure of the selectivity of that ligand with regard to the  $\beta$  subunits. These ratios are shown in Table 2. We also compared the affinities of these agonists for the heterologously expressed  $\alpha 3\beta 4$  subunit combination to their affinities for the rat forebrain receptor. An  $\alpha 3\beta 4$  subtype is found in many sympathetic ganglia, while an  $\alpha 4\beta 2$  subtype is the predominant receptor in rat forebrain; therefore, the affinity ratios of drugs at these subtypes can help to predict the likelihood of possibly limiting autonomic nervous system side effects of drugs aimed at the predominant receptor in forebrain.

**Table 1.** Binding affinities ( $K_i$ , nM) of (–)-nicotine (1), (±)-epibatidine (2) and 3, 4, 6-8, 11, 12 at heterologously expressed nAChR subtypes and rat forebrain<sup>a</sup>



Ligand	R =	$K_i$ (nM)						Rat forebrain
		$\alpha 2\beta 2$	$\alpha 2\beta 4$	$\alpha 3\beta 2$	$\alpha 3\beta 4$	$\alpha 4\beta 2$	$\alpha 4\beta 4$	
1	N/A	12	112	47	443	10	40	13
2	N/A	0.025	0.095	0.035	0.565	0.061	0.157	0.060
7	N/A	0.073	18.4	0.208	77.7	0.142	8.04	0.248
8	$\text{---H}$	1.07	209.0	9.04	835.0	1.40	205.0	5.15
10	$\text{---Br}$	1.32	546	29.3	2,040	1.56	345	7.24
18	$\text{---C}\equiv\text{CH}$	0.75	434	10.7	3,080	1.02	473	3.65
11	$\text{---}\equiv\text{---Ph}$	4.52	437	4.96	2,460	0.936	369	6.40
12	$\text{---}\equiv\text{---(CH}_2)_3\text{Me}$	13.4	1,720	20.3	9,560	2.61	1410	6.81
13	$\text{---}\equiv\text{---CH}_2\text{NHBoc}$	1.19	8,240	7.27	59,900	2.07	8280	3.71
14	$\text{---}\equiv\text{---CH}_2\text{OH}$	2.43	1,880	7.64	18,200	0.954	1690	3.16
15	$\text{---}\equiv\text{---C(Me)}_2\text{OH}$	1.93	5,890	19.70	32,600	1.34	5060	8.39
16	$\text{---}\equiv\text{---(CH}_2)_4\text{OH}$	2.87	3,230	12.6	40,200	0.81	1270	3.56
17	$\text{---}\equiv\text{---(CH}_2)_6\text{OH}$	26.8	7,800	52.1	62,700	6.50	3560	21.70
19	$\text{---}\equiv\text{---(CH}_2)_8\text{OH}$	3.33	1,150	13.40	20,000	0.75	968	5.39

<sup>a</sup>  $K_d$  values (nM) for [<sup>3</sup>H]-epibatidine used for calculating  $K_i$  values were 0.02 for  $\alpha 2\beta 2$ , 0.08 for  $\alpha 2\beta 4$ , 0.03 for  $\alpha 3\beta 2$ , 0.30 for  $\alpha 3\beta 4$ , 0.04 for  $\alpha 4\beta 2$  and 0.09 for  $\alpha 4\beta 4$ . The  $K_i$  values of (–)-nicotine (1) and epibatidine (2) shown were the mean of 3 to 6 independent measurements. The  $K_i$  values of 7, 8, and 10-19 shown were the mean of 3 independent measurements.

**Table 2.** Binding affinity ratios for nAChR  $\alpha$  subunits paired with  $\beta 2$  or  $\beta 4$  subunits and the  $\alpha 3\beta 4$  subunit combination versus the rat forebrain (primary  $\alpha 4\beta 2$ )

Ligand	Affinity ratio <sup>a</sup>				cLogP <sup>b</sup>
	$\alpha 2\beta 4$ / $\alpha 2\beta 2$	$\alpha 3\beta 4$ / $\alpha 3\beta 2$	$\alpha 4\beta 4$ / $\alpha 4\beta 2$	$\alpha 3\beta 4$ /Forbrai n	
1	9	9	4	34	0.88
2	4	16	3	9	1.55
7	252	374	57	313	0.725
8	195	92	146	162	1.83
10	414	70	221	282	2.73
18	579	288	464	844	2.10
11	97	496	423	384	4.47
12	128	471	540	1,404	4.08
13	6,924	8,240	4,000	16,146	2.48
14	774	2,382	1,772	5,760	0.64
15	3,052	1,655	3,776	3,886	1.35
16	1,125	3,190	1,568	11,292	2.23
17	291	1,203	548	2,890	4.34
19	345	1,493	1,290	3,710	2.99

<sup>a</sup> Ratio of the corresponding  $K_i$  values.

<sup>b</sup> <http://www.daylight.com/daycgi/clogp>.

As shown in Tables 1 and 2, neither nicotine (1) nor epibatidine (2) shows any significant selectivity among the six rat nAChR subtypes and rat forebrain (< 45-fold). A-85380 (7) and A-84543 (8) possessed very high affinity for all three of the nAChR subtypes containing  $\beta 2$  subunits but much lower affinity for the subtypes containing  $\beta 4$  subunits, although the best selectivities among the six nAChR subtypes and rat forebrain are still less than 400-fold. The improved selectivity suggests the possibility of developing subtype-selective ligands and therapeutically useful drugs. As a matter of fact, 7 and 8, as the novel lead compounds, have caused extensive investigation since their discovery in the mid 1990s. Introduction of additional substituent groups at the C5 position of the pyridyl ring of 8 resulting 10-19 didn't cause any significant difference on the binding affinities at the  $\alpha 4\beta 2$  containing subtype or the rat forebrain (within 5-fold). These results are in accord with the previous conclusion that the C5 position of the pyridyl ring of 8 could tolerate substitutions without losing affinity for  $\alpha 4\beta 2$  receptor subtype. However, it is noteworthy that the subtype selectivities of the derivatives 10-19 among the six heterologously

expressed neuronal nAChR subtypes and rat forebrain are much dependent on the properties of the substituent groups. First of all, the presence of a bulky substitutions at the C5 position of pyridyl part slightly improved the nAChR subtype selectivity for  $\alpha 4\beta 2$  or the receptors in rat forebrain over the ganglionic  $\alpha 3\beta 4$ , although the steric volume of substitutions has little effect on  $\alpha 4\beta 2$  nAChR binding affinity. Secondly, the ligands 13-17 and 19 with appendages containing additional polar groups, such as hydroxyl group and amide group, show significantly improved affinity ratios, e.g.  $\alpha 2\beta 4/\alpha 2\beta 2$ ,  $\alpha 3\beta 4/\alpha 3\beta 2$ ,  $\alpha 4\beta 4/\alpha 4\beta 2$ , and  $\alpha 3\beta 4$ /forbrain, in comparison to 8. For example, the affinity ratios, as compared in Table 2, for 13 are over 4000 and up to 16,000. These high active and selective analogues containing appropriately functionalized side-chain appendages are quite interesting, because in addition to their general use as pharmacological tools, they can be used to make fluorescent probes and affinity columns for certain nAChR subtypes, as well as for PET imaging study after labeled with  $^{11}\text{C}$  or  $^{18}\text{F}$ . The 5-(6-hydroxy-1-hexynyl) derivative 16 is one of the best ligands possessing not only high affinity for the  $\alpha 4\beta 2$  subtype but also high selectivity among the nAChR subtypes compared. Its analogue 17 with a prolonged (10-carbon) side-chain appendage shows both lower affinity and less subtype selectivity at the six heterologously expressed nAChR subtypes and rat forebrain. The saturated analogue 19 shows similar binding affinities for the  $\beta 2$  containing subtypes as those of 16, but the former is a little less selective.

The 6-hydroxy-1-hexynyl substituent at the C5 position of the pyridine ring of 16 is an optimum group for attaining both the expected high binding affinity at the  $\alpha 4\beta 2$  receptor and the excellent subtype-selectivity. Therefore, 5-(6-hydroxy-1-hexynyl) substituted A-85380 analogue 26, *N*-demethyl 5-(6-hydroxy-1-hexynyl) substituted A-84543 analogue 27 were prepared and evaluated at the six defined rat nicotinic receptor subtypes and rat forebrain. The binding affinity results, together with the subtype selectivity of  $\alpha 3\beta 4$  vs the receptors in rat forebrain, are summarized in Table 3. The *N*-demethyl derivative 27 shows a little higher not only binding affinities at the nAChR subtypes but also subtype selectivity of  $\alpha 3\beta 4$  vs rat forebrain than its *N*-methyl analogue 16. Similar to 16 and 27, the four-membered ring analogue 26 possessed much higher affinities at receptors composed of an  $\alpha$  subunit in combination with the  $\beta 2$  subunit than the  $\beta 4$  subunit. In fact, 26 is the most selective nAChR agonist known at  $\alpha 4\beta 2$  vs ganglionic  $\alpha 3\beta 4$  receptors (54,000-fold) while



possessed the similar high binding affinity as epibatidine (2) and A-85380 (7) at the  $\alpha 4\beta 2$  subtype.

Table 3. Binding affinities ( $K_i$ , nM) of 16, 26, 27, 31, 34, 36, 41, 42 at heterologously expressed nAChR subtypes and rat forebrain<sup>a</sup>

Ligand	$K_i$ (nM)							Affinity ratio ( $\alpha 3\beta 4$ /Forebrain) <sup>b</sup>	cLogP <sup>c</sup>
	$\alpha 2\beta 2$	$\alpha 2\beta 4$	$\alpha 3\beta 2$	$\alpha 3\beta 4$	$\alpha 4\beta 2$	$\alpha 4\beta 4$	Forebrain		
16	2.87	3,230	12.6	40,200	0.81	1270	3.56	11,292	2.23
26	0.06	269	0.53	4,840	0.09	74	-	53,778	1.12
27	1.51	835	2.69	16,100	0.665	778	1.15	14,000	1.68
31	0.352	45.10	0.146	266.0	0.166	15.40	0.215	1,237	1.15
34	16.90	67.40	19.8	95.40	67.70	61.80	52.00	2	1.15
36									3.49
41	0.796	197	0.635	5,490	0.201	118	0.362	15,166	2.38
42	3.50	680	5.27	7,580	0.907	721	3.45	2,197	2.94

<sup>a</sup>  $K_d$  values (nM) for [<sup>3</sup>H]-epibatidine used for calculating  $K_i$  values were 0.02 for  $\alpha 2\beta 2$ , 0.08 for  $\alpha 2\beta 4$ , 0.03 for  $\alpha 3\beta 2$ , 0.30 for  $\alpha 3\beta 4$ , 0.04 for  $\alpha 4\beta 2$  and 0.09 for  $\alpha 4\beta 4$ . The  $K_i$  values were the mean of 3 independent measurements. <sup>b</sup> Ratio of the corresponding  $K_i$  values. <sup>c</sup> <http://www.daylight.com/daycgi/clogp>.

If epibatidine (2) and the 3-pyridyl ethers 7 and 8 bind at nAChRs in common manners, the significant improvement of the subtype selectivity of 16, 26, and 27 by introducing a bulky hydrophilic 6-hydroxy-1-hexynyl group at the C5 position of the pyridyl ring should also apply to the corresponding epibatidine analogues. It is noteworthy that, although a lot of epibatidine analogues have been prepared with the expectation to improve their subtype selectivity, in most reports, pharmacological investigations, if conducted at all, are limited to measurements at the  $\alpha 4\beta 2$  receptor or only one or two other nAChR subtypes. A very recent study reveals that introduction of a bulky phenyl group at the C5 position of the pyridyl ring of epibatidine results in ligands with antagonist action. On the other hand, it has been shown that dechloroepibatidine binds with similar affinity as epibatidine at the  $\alpha 4\beta 2$  nAChR subtype. Thus, the 5-(6-hydroxy-1-hexynyl) substituted dechloroepibatidine analogues 31 was prepared and evaluated at the six rat nicotinic receptor subtypes and rat forebrain. As shown in Table 3, 31 also possessed subnanomolar affinities at the  $\beta 2$  containing subtypes although there are 3-14 folds less active than epibatidine (2) at each  $\beta 2$

containing subtypes. It is noteworthy that 31 was quite selective for an  $\alpha$  subunit paired with the  $\beta 2$  versus the  $\beta 4$  subunit, and the affinity ratios were up to 1,800. While epibatidine itself activates and binds to most nAChR subtypes with picomolar affinity ( $K_i$  ratios less than 20). 6-(6-Hydroxy-1-hexynyl) substituted dechloroepibatidine analogue 34, 200-1000 folds lower binding affinities than epibatidine at the nAChRs, didn't show much subtype selectivity among the neuronal nAChRs interest (less than 6-fold). This result is in agreement with the previous results that introduction of a bulky substituent at C6-position of the pyridine ring of both epibatidine and nicotine resulted in markedly decreased nAChR binding affinities. Together with the present results, we can conclude that the nicotine analogues, epibatidine analogues, and the 3-pyridyl ether analogues herein are binding in a similar fashion at the nAChRs. The C5-position, if not the only position, of the pyridyl ring of nicotine, epibatidine, and the 3-pyridyl ether analogues (e.g. 7 and 8) could tolerate an additional large polar group to obtain significant subtype selectivity without losing the binding affinity at the  $\alpha 4\beta 2$  subtype.

All of the three fluoride analogues of 16, 26, and 27, i.e. compounds 36, 41, and 42, show not only subnanomolar affinities for  $\alpha 4\beta 2$  nAChR subtype but also excellent selectivities (up to 15,000-fold) for the receptors in rat forebrain over  $\alpha 3\beta 4$  subtype. The excellent receptor affinity and subtype selectivity of these fluoride analogues are very useful as they are potential agents for PET imaging study in the diagnosis of certain CNS disorders. It is noteworthy that the selective ligands 14-16 could also be extremely useful for the PET imaging study by labeling the *N*-methyl as  $^{11}\text{C}$ -methyl, as these ligands with lower lipophilicity (lower cLogP values) which is desirable to decrease nonspecific binding of the radioligands.

The therapeutic potential of nicotinic ligands depends substantially on the ability to affect selectively certain receptor subtypes with beneficial effects. While nicotine, epibatidine, and some 3-pyridyl ethers show good affinity for the neuronal nAChRs, they generally lack selectivity. Along with our objective in the design of subtype selective nAChR ligands, we discovered that introduction of a bulky hydrophilic group, like 6-hydroxy-1-hexynyl, at the C5 position of the pyridyl ring of nicotine (1), epibatidine (2), and the 3-pyridyl ether analogues (7 and 8) could significantly improve nAChR subtype selectivity at receptors composed of an  $\alpha$  subunit in combination with the  $\beta 2$  subunit than the  $\beta 4$  subunit without losing the binding affinities at the  $\alpha 4\beta 2$  subtype. For example,

compounds 26, 27, and 31 were 2 orders of magnitude more selective for  $\alpha 4\beta 2$  over  $\alpha 3\beta 4$  than the corresponding parent compounds 7, 8, and 2. These ligands with high affinity and selectivity are quite interesting because, in addition to their general use as pharmacological tools, they containing appropriately functionalized side-chain appendages could be used to  
5 make fluorescent probes and affinity columns for certain nAChR subtypes. In light of the high affinity and selectivity found for ligands 14-16 and the fluorinated analogues 36, 41, and 42, their use in brain PET imaging studies is an aspect of the present invention.

### Synthesis of Compounds

10 The compounds of the invention may be prepared by any conventional method useful for the preparation of analogous compounds and as described in the examples below.


Starting materials for the processes described in the present patent application are known or can be prepared by known processes from commercially available materials.

15 A compound of the invention can be converted to another compound of the invention using conventional methods.


The products of the reactions described herein are isolated by conventional means such as extraction, crystallization, distillation, chromatography, and the like.

Examples of the nicotinic ACh receptor ligands of the present invention may be prepared by the general methods described in the Schemes hereinafter.


20



**Scheme 1. Reagents and conditions:** (i) 2-chloro-5-iodopyridine, *n*-BuLi, THF, -78 °C, 86%. (ii) *t*-BuOK, THF, -78 °C to rt, 2 h, 98%. (iii) BH<sub>3</sub>·THF, THF, rt, overnight, then aq. NaOH, 35% H<sub>2</sub>O<sub>2</sub>, 39%. (iv) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h. (v) Dess-Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 96%. (vi) silica gel, rt, 2 days. (vii) L-Selectride, THF, -30 to 0 °C, 91%.



**Scheme 2. Reagents and conditions:** (i) L-Selectride, THF, -30 to 0 °C, 92%. (ii) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h. (iii) NaBH<sub>4</sub>, THF, rt, 95% (diastereoselectivity 3:1).



5

**Scheme 3. Reagents and conditions:** (ii)  $\text{SmI}_2$  (2 equiv), THF-MeOH,  $-78^\circ\text{C}$  to rt, 95%.  
 (iii) Reductive Heck reaction, see Table 1.


10 **Table 1. Reductive Heck reaction on 24 and 27**

Entry	Compound	Conditions	Products (ratio) <sup>a</sup>	Yield (%) <sup>b</sup>
1	24	$\text{Pd}(\text{OAc})_2$ , 2-chloro-5-iodopyridine, $\text{HCO}_2\text{Na}$ , $n\text{-Bu}_4\text{NCl}$ , DMF, $100^\circ\text{C}$	25:26 (5.0:1)	56
2	24	$\text{Pd}(\text{OAc})_2(\text{PPh})_2$ , 2-chloro-5-iodopyridine, piperidine, $\text{HCO}_2\text{H}$ , DMF, $75^\circ\text{C}$	25:26 (2.5:1)	38
3	24	$\text{Pd}(\text{PPh})_4$ , 2-chloro-5-iodopyridine, piperidine, $\text{HCO}_2\text{H}$ , DMF, $75^\circ\text{C}$	25:26 (0.9:1)	47
4	27	$\text{Pd}(\text{PPh})_4$ , 2-chloro-5-iodopyridine, piperidine, $\text{HCO}_2\text{H}$ , DMF, $75^\circ\text{C}$	28:29 (12:1) <sup>c</sup>	92


<sup>a</sup> Ratios were determined from the  $^1\text{H}$  NMR spectra of the product mixtures after chromatography.

<sup>b</sup> Overall yields were of isolated material after chromatography.


15 <sup>c</sup> Ratio was determined from the  $^1\text{H}$  NMR spectrum of the crude reaction products.



**Scheme 4.** Reagents and conditions: (i) HOCH<sub>2</sub>CH<sub>2</sub>OH, (EtO)<sub>3</sub>CH, *p*-TsOH (cat.), THF, 64%. (ii) 8, Pd(PPh<sub>3</sub>)<sub>4</sub> (cat.), piperidine, HCO<sub>2</sub>H, DMF, 75 °C, 92%. (iii) 1. HClO<sub>4</sub>; 2. Boc<sub>2</sub>O, Et<sub>3</sub>N, THF, 77-83% for two steps. (iv) see Table 2. (v) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, 93-97%.




**Scheme 5.**




Scheme 6. Retrosynthesis.


## Method 1



## Method 2




Scheme 7. Two Methods for the Synthesis of Ketone 38.



- 5 **Scheme 8. Reagents and conditions:** (i) MeI, Ag<sub>2</sub>CO<sub>3</sub>, CHCl<sub>3</sub>, 71-93%; (ii) *n*-BuLi, THF, then (CH<sub>2</sub>O)<sub>n</sub>, -78 °C to rt, 49-51%; (iii) Br<sub>2</sub>, EtOH, 88-91%; (iv) TBSCl, imidazole, DMAP, DMF, 98%; (v) *n*-BuLi, THF, then 15, -78 °C to rt, 80-86%; (vi) MsCl, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 84-87%; (vii) *n*-Bu<sub>4</sub>NF, THF, 100%; (viii) PPh<sub>3</sub>, CBr<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 87-88%; (ix) *n*-Bu<sub>3</sub>SnH, AIBN, toluene, reflux, 85-87%.



10



- 15 **Scheme 9. Reagents and conditions:** (i) *n*-BuLi, THF, -78 °C, 1.5 h; then 38, -78 °C, 1 h, then rt, 1 h, 80-86%. (ii) MsCl, Et<sub>3</sub>N, DMAP (cat.), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 6 h, 84-87%. (iii) *n*-Bu<sub>4</sub>NF, THF, rt, 6 h, 98-100%. (iv) PPh<sub>3</sub>, CBr<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 85-91%. (v) *n*-Bu<sub>3</sub>SnH, AIBN (cat.), toluene, reflux, overnight, 84-87%.


20






Scheme 10.

5



Scheme 11.

10



Scheme 12. Synthesis A-84543 analogs.

### Binding Affinity Assays

Many different assay methods can be used to determine the activity of the compounds of the present invention. These assay methods include, for example, the following but also include other methods known to one of ordinary skill in the art.

Nicotinic ACh receptors in the brain are pentameric structures composed of subunits distinct from those found in skeletal muscles. The existence of eight  $\alpha$ -subunits ( $\alpha 2$ - $\alpha 9$ ) and three  $\beta$ -subunits ( $\beta 2$ - $\beta 4$ ) in the mammalian brain has been described.

The predominant subtype with high affinity for nicotine is comprised of three  $\alpha$ -subunits and two  $\beta$ -subunits.

The affinity of compounds of the invention for nicotinic ACh receptors may be investigated in three tests for in vitro inhibition of  $^3\text{H}$ -epibatidine binding,  $^3\text{H}$ - $\alpha$ -bungarotoxin binding and  $^3\text{H}$ -cytisine binding as described below:

#### In Vitro Inhibition of $^3\text{H}$ -cytisine Binding

The predominant subtype with high affinity for nicotine is comprised of  $\alpha 4$  and  $\beta 2$  subunits. nAChRs of the latter type may selectively be labelled by the nicotine agonist  $^3\text{H}$ -cytisine.

Tissue Preparation: Preparations may be performed at 0-4 °C unless otherwise indicated. Cerebral cortices from male Wistar rats (150-250 g) may be homogenized for 20 sec in 15 mL Tris, HCl (50 mM, pH 7.4) containing 120 mM NaCl, 5 mM KCl, 1 mM MgCl<sub>2</sub> and 2.5 mM CaCl<sub>2</sub> using an Ultra-Turrax homogenizer. The homogenate may then be centrifuged at 27,000 x g for 10 min. The supernatant may then be discarded and the pellet resuspended in fresh buffer and centrifuged a second time. The final pellet may be resuspended in fresh buffer (35 mL per g of original tissue) and used for binding assays.

Assay: Aliquots of 500  $\mu\text{L}$  homogenate may be added to 25  $\mu\text{L}$  of test solution and 25  $\mu\text{L}$  of  $^3\text{H}$ -cytisine (1 nM, final concentration), mixed and incubated for 90 min at 2 °C. Non-specific binding may then be determined using (-)-nicotine (100  $\mu\text{M}$ , final concentration). After incubation the samples may be added to 5 mL of ice-cold buffer and poured directly onto Whatman GF/C glass fiber filters under suction and immediately washed with 2 x 5

mL ice-cold buffer. The amount of radioactivity on the filters may then be determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.

5 In Vitro Inhibition of  $^3\text{H}$ - $\alpha$ -bungarotoxin Binding Rat Brain

$\alpha$ -Bungarotoxin is a peptide isolated from the venom of the Elapidae snake *Bungarus multicinctus* (Mebs et al., Biochem. Biophys. Res. Commun., 44(3), 711 (1971)) and has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist.  $^3\text{H}$ - $\alpha$ -Bungarotoxin binds to a single site in rat brain with a unique  
10 distribution pattern in rat brain (Clarke et al., J. Neurosci. 5, 1307-1315 (1985)).

$^3\text{H}$ - $\alpha$ -Bungarotoxin labels nAChR are formed by the  $\alpha 7$  subunit isoform found in the brain and the isoform in the neuromuscular junction (Changeaux, Fidia Res. Found. Neurosci. Found. Lect. 4, 21-168 (1990). Functionally, the  $\alpha 7$  homo-oligomer expressed in oocytes has a calcium permeability greater than neuromuscular receptors and, in some  
15 instances greater than NMDA channels (Seguela et al., J. Neurosci. 13, 596-604 (1993)).

Tissue Preparation: Preparations may be performed at 0-4 °C unless otherwise indicated. Cerebral cortices from male Wistar rats (150-250 g) may be homogenized for 10 sec in 15 mL 20 mM Hepes buffer containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO<sub>4</sub> and 2.5 mM CaCl<sub>2</sub> (pH 7.5) using an Ultra-Turrax homogenizer. The tissue  
20 suspension may then be centrifuged at 27,000 x g for 10 min. The supernatant is discarded and the pellet is washed twice by centrifugation at 27,000 x g for 10 min in 20 mL fresh buffer, and the final pellet may be resuspended in fresh buffer containing 0.01% BSA (35 mL per g of original tissue) and used for binding assays.

Assay: Aliquots of 500  $\mu\text{L}$  homogenate may be added to 25  $\mu\text{L}$  of test solution and 25  
25  $\mu\text{L}$  of  $^3\text{H}$ - $\alpha$ -bungarotoxin (2 nM, final concentration), mixed and incubated for 2 h at 37 °C. Non-specific binding may then be determined using (-)-nicotine (1 mM, final concentration). After incubation the samples may be added to 5 mL of ice-cold Hepes buffer containing 0.05% PEI and poured directly onto Whatman GF/C glass fibre filters (presoaked in 0.1% PEI for at least 6 h) under suction and immediately washed with 2 x 5  
30 mL ice-cold buffer. The amount of radioactivity on the filters may then be determined by

conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.

#### In Vitro Inhibition of $^3\text{H}$ -epibatidin Binding

5 As discussed previously, Epibatidin is an alkaloid that was first isolated from the skin of the Ecuadoran frog *Epipedobates tricolor* and was found to have very high affinity for neuronal nicotinic receptors, where it acts as a potent agonist. It is believed that  $^3\text{H}$ -epibatidin binds to two sites in rat brain, both of which have pharmacological profiles consistent with neuronal nicotinic receptors and a similar brain regional distribution  
10 (Hougling et al., *Mol. Pharmacol.* 48, 280-287 (1995)).

The high affinity binding site for  $^3\text{H}$ -epibatidin is most certainly binding to the  $\alpha 4\beta 2$  subtype of nicotinic receptors. The identity of the low affinity site is still believed to be unknown. The inability of  $\alpha$ -bungarotoxin to compete for  $^3\text{H}$ -epibatidin binding sites may indicate that neither site measured represents the nicotinic receptor composed of  $\alpha 7$   
15 subunits.


Tissue preparation: Preparations may be performed at 0-4 °C unless otherwise indicated. The forebrain (+cerebellum) from a male Wistar rat (150-250 g) may be homogenized for 10-20 sec in 20 mL Tris, HCl (50 mM, pH 7.4) using an Ultra-Turrax homogenizer. The tissue suspension may then be centrifuged at 27,000 x g for 10 min. The  
20 supernatant is then discarded and the pellet may then be washed three times by centrifugation at 27,000 x g for 10 min in 20 mL fresh buffer, and the final pellet may be resuspended in fresh buffer (400 mL per g of original tissue) and used for binding assays.

Assay: Aliquots of 2.0 mL homogenate may be added to 0.100 mL of test solution and 0.100 mL of  $^3\text{H}$ -epibatidin (0.3 nM, final concentration), mixed and incubated for 60  
25 min at room temperature. Non-specific binding may then be determined using (-)-nicotine (30  $\mu\text{M}$ , final concentration). After incubation the samples may then be poured directly onto Whatman GF/C glass fibre filters (presoaked in 0.1% PEI for at least 20 min) under suction and immediately washed with 2 x 5 mL ice-cold buffer. The amount of radioactivity on the filters may be determined by conventional liquid scintillation counting.  
30 Specific binding is total binding minus non-specific binding.

**Table 2.** Binding affinities of (±)-epibatidine (1) and epibatidine analogs 2-11 to six nAChR subtypes.

Ligand	Introduced Group	K <sub>i</sub> (nM)					
		α2β2	α2β4	α3β2	α3β4	α4β2	α4β4
1		0.025	0.095	0.035	0.565	0.061	0.157
2	3- <i>exo</i> -OH	814	617	1133	1171	2371	515
3	3- <i>endo</i> -OH	2.5	15.3	7.3	39.1	2.9	11.2
6	5- <i>exo</i> -OH	16.9	67.5	19.3	223.9	29.3	72.8
7	5- <i>endo</i> -OH	93.7	238	285	916	70.9	247
8	6- <i>exo</i> -OH	6.3	39.7	8.9	143.9	12.6	45.6
9	6- <i>endo</i> -OH	1.53	5.85	1.36	27.29	0.92	5.57
10	5- <i>exo</i> -F	0.86	5.59	0.65	10.36	1.73	1.22
11	6- <i>exo</i> -F	0.22	0.48	0.15	2.48	0.33	0.17
4	5- <i>oxo</i>	642	1140	1890	4430	7080	3240
5	6- <i>oxo</i>	1010	3240	1500	8870	2020	3560

5

**Table 3.** Binding affinities ( $K_i$ , nM) of (-)-nicotine, (±)-epibatidine and four constrained epibatidine analogues to six nAChR subtypes<sup>a</sup>.

Ligand	α2β2	α2β4	α3β2	α3β4	α4β2	α4β4
Nicotine	12 +/- 2	112 +/- 21	47 +/- 11	443 +/- 60	10 +/- 2	40 +/- 6
1	0.025 +/- 0.001	0.095 +/- 0.017	0.035 +/- 0.011	0.565 +/- 0.121	0.061 +/- 0.009	0.157 +/- 0.006
37a	290 +/- 5	717 +/- 36	354 +/- 10	2280 +/- 220	73 +/- 11	637 +/- 302
37b	59 +/- 7	32 +/- 3	530 +/- 81	201 +/- 16	295 +/- 85	41 +/- 14
58a	12600 +/- 5300	10700 +/- 1000	19700 +/- 4500	14900 +/- 4500	29200 +/- 4300	10500 +/- 4500
58b	2690 +/- 230	7180 +/- 190	4070 +/- 850	13800 +/- 1700	6990 +/- 2000	9460 +/- 3700

10

<sup>a</sup>  $K_d$  values (nM) for [<sup>3</sup>H]-epibatidine used for calculating  $K_i$  values were 0.02 for α2β2, 0.08 for α2β4, 0.03 for α3β2, 0.30 for α3β4, 0.04 for α4β2 and 0.09 for α4β4 (Xiao and Kellar, 2003, manuscript in preparation). The  $K_i$  values of (-)-nicotine and epibatidine (1) shown were the mean ± SEM of 3 to 6 independent measurements. The  $K_i$  values of 20a,b and 23a,b shown were the mean ± SEM of 3 independent measurements.

15

WO 2005/000806
































Table 4. Binding affinities of (±)-epibatidine (1) and bivalent analogues 59a-d to six nAChR subtypes.

Ligand	n =	K <sub>i</sub> (nM)					
		α2β2	α2β4	α3β2	α3β4	α4β2	α4β4
1	N/A	0.025	0.095	0.035	0.565	0.061	0.157
59a	0	1.3	2.9	5.6	11.8	10.7	18.0
59b	1	6.1	15.7	5.2	62.9	8.7	23.3
59c	4	4.1	37.4	6.6	64.7	7.2	31.9
59d	8	5.8	24.2	6.8	67.7	10.3	18.7














Table 5. K<sub>i</sub> Values (nM) of Ligand Binding to Rat nAChR Subtypes.







Compounds	ID (PDSP#)	K <sub>i</sub> (nM)						
		α2β2	α2β4	α3β2	α3β4	α4β2	α4β2*	α4β4
	Cytisine	0.5706	3.508	8.064	210.1	1.346	2.573	1.519
	ZW-16	1335	2625	>1000	>10000	570.9	1496	732.3
	ZW-17	2980	14020	>1000	>10000	3110	4548	3227

	ZW-18	318.2	3476	>1000	>10000	468.3	935.8	746.2
	ZW-19	239.9	1432	>1000	>10000	383.2	603.1	467.9
	ZW-36 (02-0528)	51.0	773.0	3,590.0	26,100.0	1,790.0	173.0	149.0
	ZW-37 (02-0529)	39.10	314.0	3,010.0	11,700.0	1,010.0	110.00	73.40
	ZW-24 (02-0482)	814	617	1,133	1,171	2,371	2,064	515
	ZW-25 (02-0483)	2.49	15.3	7.31	39.1	2.92	4.79	11.2
	ZW-26 (02-0484)	93.7	238	285	916	70.9	134	247
	ZW-27 (02-0485)	1.532	5.850	1.359	27.290	0.916	4.108	5.574
	ZW-28 (02-0486)	16.950	67.51	19.280	223.90	29.330	69.020	72.75
	ZW-29 (02-0487)	6.298	39.73	8.884	143.90	12.580	22.930	45.57
	ZW-30 (02-0488)	0.864	5.590	0.646	10.360	1.734	2.109	1.225
	ZW-31 (02-0489)	0.218	0.481	0.149	2.476	0.328	0.668	0.172
	ZW-32 (02-0501)	2,464	7,088	3,664	14,890	5,048	12,122	9,564
	ZW-33 (02-0502)	59.41	32.24	540.5	200.7	210.35	575.85	39.78

	<b>ZW-34</b> (02-0503)	12,784	11,610	15,985	36,700	28,020	54,350	10,200
	<b>ZW-35</b> (02-0504)	293.6	693.5	345.35	2,167	67.42	339.5	672.5
	<b>ZW-38</b> (02-0530)	4.120	37.400	6.610	64.700	7.2	14.200	31.900
	<b>ZW-39</b> (02-0531)	16.900	67.400	19.8	95.400	67.700	52.000	61.800
	<b>ZW-56</b> (02-0581)	6.08	15.70	5.17	62.90	8.66	10.10	23.30
	<b>ZW-57</b> (02-0582)	5.78	24.20	6.75	67.70	10.30	13.90	18.70
	<b>ZW-80</b> (03-0897)	642	1140	1890	4430	7080	4570	3240
	<b>ZW-81</b> (03-0898)	1010	3240	1500	8870	2020	1350	3560
	<b>ZW-82</b> (03-0899)	30	93.8	147	173	57.3	304	53.1
	<b>ZW-83</b> (03-0900) (mix)	1.28	2.86	5.56	11.8	10.7	29.1	18
	<b>ZW-84</b> (03-0901)	7.08	16.6	21.1	67.6	21.9	112	84.5
	<b>ZW-85</b> (03-1066) A-84543	1.07	209.0	9.04	835.0	1.40	5.15	205.0
	<b>ZW-86</b> (03-1067)	1.32	546.0	29.3	2040.0	1.56	7.24	345.0
	<b>ZW-87</b> (03-1068)	0.75	434.0	10.70	3080.0	1.02	3.65	473.0



	<b>ZW-88</b> (03-1069)	1.93	5890.0	19.70	32600.0	1.34	8.39	5060.0
	<b>ZW-89</b> (03-1070)	2.43	1880.0	7.64	18200.0	0.954	3.16	1690.0
	<b>ZW-90</b> (03-1071)	2.87	3230.0	12.6	40200.0	0.81	3.56	1270.0
	<b>ZW-91</b> (03-1072)	3.33	1150.0	13.40	20000.0	0.75	5.39	968.0
	<b>ZW-92</b> (03-1073)	406.0	31600.0	870.0	89600.0	201.0	505.0	31900.0
	<b>ZW-93</b> (03-1074)	26.8	7800.0	52.1	62700.0	6.50	21.70	3560.0
	<b>ZW-94</b> (03-1230)	0.352	45.10	0.146	266.0	0.166	0.215	15.40
	<b>ZW-95</b> (03-1231)	0.323	24.90	0.165	122.0	0.151	0.314	7.91
	<b>ZW-96</b> (03-1270)	5,410	28,100	5,510	10,700	7,870	18,400	46,500
	<b>ZW-97</b> (03-1271)	1.19	8,240	7.27	59,900	2.07	3.71	8,280
	<b>ZW-98</b> (03-1272)	4.52	437	4.96	2,460	0.936	6.40	369
	<b>ZW-99</b> (03-1274)	7.52	7,400	47.4	127,000	7.18	41.4	6,130
	<b>ZW-100</b> (03-1275)	13.4	1,720	20.3	9,560	2.61	6.81	1,410
	<b>ZW-101</b> (03-1276)	1.51	835	2.69	16,100	0.665	1.15	778

	ZW-102 (03-1277)	3.50	680	5.27	7,580	0.907	3.45	721
	ZW-103 (03-1278)	0.06	269	0.53	4,840	0.09	-	74
	ZW-104 (03-1279)	0.796	197	0.635	5,490	0.201	0.362	118
	A-85380	0.073	18.4	0.208	77.7	0.142	0.248	8.04
	Nicotine	12	112	47	443	10	-	40
	Epibatidine	0.025	0.095	0.035	0.565	0.061	0.060	0.157

\* Rat forebrain, mainly  $\alpha 4\beta 2$ .

Table 6. Summary Table of Competition Binding with [3H]-Epibatidine.\*  
Concentration of [3H]-EB: 0.099 nM, 0.091 nM # of Concentration of Tested Ligand:

Samples (PDSP#)	Concentration Range	K <sub>i</sub> (nM) *						
		$\alpha 2\beta 2$	$\alpha 2\beta 4$	$\alpha 3\beta 2$	$\alpha 3\beta 4$	$\alpha 4\beta 2$	$\alpha 4\beta 2^{**}$	$\alpha 4\beta 4$
ZW-85	0.00197 – 100 $\mu$ M	1.070	209.000	9.040	835.000	1.400	5.150	205.000
ZW-86	0.00197 – 100 $\mu$ M	1.320	546.000	29.300	2040.000	1.560	7.240	345.000
ZW-87	0.00197 – 100 $\mu$ M	0.749	434.000	10.700	3080.000	1.020	3.650	473.000
ZW-88	0.00197 – 100 $\mu$ M	1.930	5890.000	19.700	32600.000	1.340	8.390	5060.000
ZW-89	0.00197 – 100 $\mu$ M	2.430	1880.000	7.640	18200.000	0.954	3.160	1690.000
ZW-90	0.00197 – 100 $\mu$ M	2.870	3230.000	12.600	40200.000	0.810	3.560	1270.000
ZW-91	0.00197 – 100 $\mu$ M	3.330	1150.000	13.400	20000.000	0.754	5.390	968.000
	0.00197 – 100 $\mu$ M	406.00	31600.00	870.00			505.00	
ZW-92		0	0	0	89600.000	201.000	0	31900.00
ZW-93	0.00197 – 100 $\mu$ M	26.800	7800.000	52.100	62700.000	6.500	21.700	3560.000
Epibatidine***		0.0	0.095	0.035	0.565	0.061	0.060	0.157
A-85380***		0.0	73 18.400	0.208	77.700	0.142	0.248	8.040

\* n = 1.

\*\* Forebrain mainly  $\alpha 4\beta 2$ .

### Dosages

The dosage of any compositions of the present invention will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration, and the form of the subject composition. Any of the subject formulations may be administered in a single dose or in divided doses. Dosages for the compositions of the present invention may be readily determined by techniques known to those of skill in the art or as taught herein.

In certain embodiments, the dosage of the subject compounds will generally be in the range of about 0.01 ng to about 10 g per kg body weight, specifically in the range of about 1 ng to about 0.1 g per kg, and more specifically in the range of about 100 ng to about 10 mg per kg.

An effective dose or amount, and any possible effects on the timing of administration of the formulation, may need to be identified for any particular composition of the present invention. This may be accomplished by routine experiment as described herein, using one or more groups of animals (preferably at least 5 animals per group), or in human trials if appropriate. The effectiveness of any subject composition and method of treatment or prevention may be assessed by administering the composition and assessing the effect of the administration by measuring one or more applicable indices, and comparing the post-treatment values of these indices to the values of the same indices prior to treatment.

The precise time of administration and amount of any particular subject composition that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a subject composition, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), route of administration, and the like. The guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.

While the subject is being treated, the health of the patient may be monitored by measuring one or more of the relevant indices at predetermined times during the treatment

period. Treatment, including composition, amounts, times of administration and formulation, may be optimized according to the results of such monitoring. The patient may be periodically reevaluated to determine the extent of improvement by measuring the same parameters. Adjustments to the amount(s) of subject composition administered and possibly to the time of administration may be made based on these reevaluations.

Treatment may be initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum therapeutic effect is attained.

The use of the subject compositions may reduce the required dosage for any individual agent contained in the compositions because the onset and duration of effect of the different agents may be complimentary.

Toxicity and therapeutic efficacy of subject compositions may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD<sub>50</sub> and the ED<sub>50</sub>.

The data obtained from the cell culture assays and animal studies may be used in formulating a range of dosage for use in humans. The dosage of any subject composition lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For compositions of the present invention, the therapeutically effective dose may be estimated initially from cell culture assays.

#### Formulation

The compositions of the present invention may be administered by various means, depending on their intended use, as is well known in the art. For example, if compositions of the present invention are to be administered orally, they may be formulated as tablets, capsules, granules, powders or syrups. Alternatively, formulations of the present invention may be administered parenterally as injections (intravenous, intramuscular or subcutaneous), drop infusion preparations or suppositories. For application by the ophthalmic mucous membrane route, compositions of the present invention may be

formulated as eyedrops or eye ointments. These formulations may be prepared by conventional means, and, if desired, the compositions may be mixed with any conventional additive, such as an excipient, a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an emulsifying agent or a coating agent.

5 In formulations of the subject invention, wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may be present in the formulated agents.

10 Subject compositions may be suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of composition that may be combined with a carrier material to produce a single dose vary depending upon the subject being treated, and the particular mode of administration.

15 Methods of preparing these formulations include the step of bringing into association compositions of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association agents with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

20 Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), each  
25 containing a predetermined amount of a subject composition thereof as an active ingredient. Compositions of the present invention may also be administered as a bolus, electuary, or paste.

In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more  
30 pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose,

mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject composition, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Suspensions, in addition to the subject composition, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and

tragacanth, and mixtures thereof.

Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent. Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for transdermal administration of a subject composition includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

The ointments, pastes, creams and gels may contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

Compositions of the present invention may alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A non-aqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers may be used because they minimize exposing the agent to shear, which may result in degradation of the compounds contained in the subject compositions.

Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically

acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronic, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.

5 Aerosols generally are prepared from isotonic solutions.

Pharmaceutical compositions of this invention suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or  
10 dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and non-aqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as  
15 glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

20


### Kits

This invention also provides kits for conveniently and effectively implementing the methods of this invention. Such kits comprise any subject composition, and a means for facilitating compliance with methods of this invention. Such kits provide a convenient and  
25 effective means for assuring that the subject to be treated takes the appropriate active in the correct dosage in the correct manner. The compliance means of such kits includes any means which facilitates administering the actives according to a method of this invention. Such compliance means include instructions, packaging, and dispensing means, and combinations thereof. Kit components may be packaged for either manual or partially or  
30 wholly automated practice of the foregoing methods. In other embodiments involving kits, this invention contemplates a kit including compositions of the present invention, and optionally instructions for their use.




**Exemplification**

The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.



**Reagents and conditions:** (i) Toluene, 80 °C; (ii) Pd-C (cat.), H<sub>2</sub>; (iii) 2-chloro-5-iodopyridine, *n*-BuLi, THF, -78 °C, 86%; (iv) *t*-BuOK, THF, -78 °C to rt, 98%; (v) BH<sub>3</sub>·THF, THF, rt, overnight, then aq. NaOH, 35% H<sub>2</sub>O<sub>2</sub>, 63%; (vi) Dess-Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, 96%; (vii) silica gel, rt; (viii) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>; (ix) L-Selectride, THF, -30 to 0 °C, 91%.



**Reagents and conditions** (i) L-Selectride, THF,  $-78^{\circ}\text{C}$  to rt, 92%; (ii)  $\text{CF}_3\text{COOH}$ ,  $\text{CH}_2\text{Cl}_2$ ; (iii)  $\text{NaBH}_4$ , THF, 95% (diastereo-selectivity 3:1); (iv) DAST,  $\text{CH}_2\text{Cl}_2$ ,  $-78^{\circ}\text{C}$  to rt, 83-87%.

**7-tert-Butoxycarbonyl-2-(p-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-2,5-diene:** A stirred mixture of p-tolylsulfonylacetylene (6g, 33 mmol) and N-tert-butoxycarbonylpyrrole (14 g, 83 mmol) was heated under  $\text{N}_2$  at  $80^{\circ}\text{C}$  for 36 h. Then the excess N-tert-butoxycarbonylpyrrole was removed in vacuo and the slurry residue was chromatographed with n-hexane-EtOAc (10:1 to 4:1) to give the product as a yellow solid (9.5 g, 83%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.75 (AB, 2H,  $J = 8.1$  Hz), 7.57 (s, 1H), 7.35 (AB, 2H,  $J = 8.1$  Hz), 6.94 (m, 1H), 6.87 (dd, 1H,  $J = 5.4, 2.7$  Hz), 5.38 (s, 1H), 5.17 (s, 1H), 2.44 (s, 3H), 1.26 (s, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  154.02, 152.80, 151.60, 145.10, 144.03, 143.18, 141.67, 130.20, 128.27, 81.56, 67.83, 67.02, 27.98, 21.81.

**7-tert-Butoxycarbonyl-2-(p-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-2-ene:** A mixture of 7-tert-butoxycarbonyl-2-(p-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-2-ene (4.2 g, 12.1 mmol),  $\text{CH}_3\text{CN}$  (160 mL), 5% Pd-C (0.4 g) was vigorously stirred under 1 atm of  $\text{H}_2$  at room temperature. After the required volume of  $\text{H}_2$  was absorbed, the reaction mixture was filtered through Celite. The filtrate was concentrated in vacuo to give a white solid (4.2 g, 100%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.81 and 7.36 (AB, 4H,  $J = 8.1$  Hz), 7.06 (d, 1H,  $J = 2.4$  Hz), 4.83 (s, 1H), 4.77 (d, 1H,  $J = 3.6$  Hz), 2.45 (s, 3H), 2.10-1.95 (m, 2H), 1.45-1.26 (m, 2H), 1.21 (s, 9H).

**7-tert-Butoxycarbonyl-2-exo-(2-chloro-5-pyridyl)-3-endo-(p-tolylsulfonyl)-7-**

**azabicyclo[2.2.1]heptane:** To a stirred solution of 5-iodo-2-chloropyridine (4.5 g, 19 mmol) in THF (135 mL) under N<sub>2</sub> at -78 °C was added dropwise *n*-BuLi (2.5 M in hexanes, 9.0 mL, 22 mmol). After 30 min a solution of 7-tert-butoxycarbonyl-2-(p-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-2-ene (5.7 g, 16 mmol) in THF (60 mL) was added dropwise to the metallated pyridine. After 1 h at -78 °C, sat. aq. NaHCO<sub>3</sub> (20 mL) was added and the solution was warmed to room temperature. The mixture was concentrated *in vacuo*, diluted with brine (100 mL), and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography with CHCl<sub>3</sub>-hexane-diethyl ether (8:6:1) to give a white foam (6.5 g, 86%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.18 (s, 1H), 7.66 and 7.28 (AB, 4H, *J* = 8.1 Hz), 7.54 (dd, 1H, *J* = 8.1, 1.8 Hz), 7.17 (d, 1H, *J* = 8.1 Hz), 4.44 (s, 1H), 4.28 (d, 1H, *J* = 4.5 Hz), 3.58 (t, 1H, *J* = 4.5 Hz), 3.32 (s, 1H), 2.67 (m, 1H), 2.41 (s, 3H), 2.05-1.70 (m, 3H), 1.42 (s, 9H).

**7-tert-Butoxycarbonyl-2-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]hept-2-ene:** To a stirred solution of 7-tert-butoxycarbonyl-2-exo-(2-chloro-5-pyridyl)-3-endo-(p-tolylsulfonyl)-7-azabicyclo[2.2.1]heptane (400 mg, 0.86 mmol) in THF (40 mL) was added *t*-BuOK (350 mg, 3.12 mmol) in one portion under N<sub>2</sub> at -78 °C. The reaction mixture was warmed slowly to room temperature and stirred at room temperature for 1 h. Then sat. aq. NH<sub>4</sub>Cl (5 mL) was added and the mixture was concentrated. The residue was dissolved in EtOAc (50 mL) and washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by chromatography with hexane-EtOAc (5:1) to give a syrup (260 mg, 98%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.42 (d, 1H, *J* = 2.4 Hz), 7.64 (dd, 1H, *J* = 8.4, 2.4 Hz), 7.30 (d, 1H, *J* = 8.4 Hz), 6.56 (s, 1H), 5.04 (s, 1H), 4.82 (s, 1H), 2.11-1.96 (m, 2H), 1.42 (s, 9H), 1.36-1.16 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 155.08, 150.15, 146.22, 143.57, 135.28, 130.86, 127.97, 124.31, 80.27, 61.15, 60.40, 28.19, 25.70, 24.21.

**7-tert-Butoxycarbonyl-2-endo-(2-chloro-5-pyridyl)-3-exo-hydroxyl-7-**

**azabicyclo[2.2.1]heptane:** To a solution of 7-tert-butoxycarbonyl-2-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]hept-2-ene (1.80 g, 5.9 mmol) in anhydrous THF (50 mL) was added

dropwise borane-THF complex (1.0 M in THF, 18 mL, 18 mmol) under N<sub>2</sub> at -78 °C. The reaction mixture was slowly warmed to room temperature and stirred at room temperature overnight. Then the reaction mixture was quenched by sequential addition of water (15 mL), sodium hydroxide solution (6.0 M, 15 mL), ethanol (10 mL), and 35% of hydrogen peroxide solution (15 mL). The mixture was stirred for a further 30 min, and then diluted with EtOAc (200 mL). The organic layer was separated and washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by chromatography with hexane-EtOAc (2:1) to give a syrup (1.20 g, 63%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.24 (d, 1H, *J* = 2.4 Hz), 7.48 (dd, 1H, *J* = 8.1, 2.4 Hz), 7.30 (d, 1H, *J* = 8.1 Hz), 4.40 (t, 1H, *J* = 4.2 Hz), 4.24 (d, 1H, *J* = 4.5 Hz), 4.05 (s, 1H), 3.20 (s, 1H), 2.5 (br s, 1H), 1.85 (m, 1H), 1.56 (m, 1H), 1.48 (s, 9H), 1.36-1.25 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 156.43, 150.03, 149.31, 138.60, 133.13, 124.27, 80.71, 79.15, 64.40, 59.90, 56.39, 28.45, 25.07, 22.39.

**7-*tert*-Butoxycarbonyl-2-*endo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one:**

To a solution of 7-*tert*-butoxycarbonyl-2-*endo*-(2-chloro-5-pyridyl)-3-*exo*-hydroxyl-7-azabicyclo[2.2.1]heptane (730 mg, 2.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added Dess-Martin periodinane (1.2 g, 2.8 mmol) and the reaction mixture was stirred at room temperature for 4 h. After removal of most of the solvent *in vacuo*, the residue was passed through a short silica gel column. The crude product was further purified by chromatography with hexane-EtOAc (4:1) to give a syrup (700 mg, 96%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.25 (d, 1H, *J* = 2.4 Hz), 7.55 (dd, 1H, *J* = 8.4, 2.4 Hz), 7.34 (d, 1H, *J* = 8.4 Hz), 4.75 (t, 1H, *J* = 4.8 Hz), 4.44 (d, 1H, *J* = 5.4 Hz), 3.85 (d, 1H, *J* = 5.1 Hz), 2.23-2.10 (m, 1H), 1.88-1.75 (m, 1H), 1.71-1.60 (m, 1H), 1.56-1.43 (m, 1H), 1.50 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 208.23, 154.87, 150.86, 149.95, 138.79, 129.06, 124.55, 81.73, 64.97, 60.58, 55.88, 28.36, 25.32, 22.76.

**7-*tert*-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one:** A solution of 7-*tert*-butoxycarbonyl-2-*endo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one (200 mg, 0.62 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was loaded on a precoated silica gel plate (size: 20 x 20 cm; layer thickness: 250 μm. Silica Gel 60 F<sub>254</sub>, Merck Co.). After 2 days at room temperature, the silica gel was removed and washed with EtOAc, and the solution was concentrated. The residue was purified by chromatography with hexane-EtOAc (5:1) to give

the recovered starting material (74 mg, 37%), followed by a white solid (126 mg, 63%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.36 (d, 1H, *J* = 2.4 Hz), 7.64 (dd, 1H, *J* = 8.4, 2.4 Hz), 7.28 (d, 1H, *J* = 8.4 Hz), 4.72 (s, 1H), 4.43 (d, 1H, *J* = 3.6 Hz), 3.18 (s, 1H), 2.20-2.0 (m, 2H), 1.90-1.75 (m, 2H), 1.45 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 206.07, 154.73, 150.59, 149.16, 137.84, 130.57, 124.40, 81.60, 63.41, 60.58, 56.87, 28.35, 28.17, 24.70. Anal. Calcd for (C<sub>16</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub>·1/5H<sub>2</sub>O) C, 58.88; H, 5.99; N, 8.58. Found: C, 59.08; H, 5.81; N, 8.54.

**7-*tert*-Butoxycarbonyl-2-*endo*-(2-chloro-5-pyridyl)-3-*endo*-hydroxyl-7-azabicyclo[2.2.1]heptane:** To a stirred solution of 7-*tert*-butoxycarbonyl-2-*endo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one (120 mg, 0.37 mmol) in anhydrous THF (10 mL) was added L-Selectride (1.0 M in THF, 520 μL, 0.52 mmol) under N<sub>2</sub> at -30 °C. The reaction mixture was slowly warmed to 0 °C in 1 h. Ethanol (2 mL) was added, followed by saturated aq. NH<sub>4</sub>Cl (2 mL) and then diluted with EtOAc (50 mL). The organic layer was separated and washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by chromatography with hexane-EtOAc (30:1) to give a syrup (110 mg, 91%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.22 (d, 1H, *J* = 2.4 Hz), 7.68 (dd, 1H, *J* = 8.4, 2.4 Hz), 7.24 (d, 1H, *J* = 8.4 Hz), 4.58 (m, 1H), 4.33 (t, 1H, *J* = 4.5 Hz), 4.21 (s, 1H), 3.34 (dd, 1H, *J* = 9.6, 4.5 Hz), 3.28 (d, 1H, *J* = 3.9 Hz), 2.23 (m, 1H), 1.76-1.53 (m, 3H), 1.47 (s, 9H). Anal. Calcd for (C<sub>16</sub>H<sub>21</sub>ClN<sub>2</sub>O<sub>3</sub>·1/4H<sub>2</sub>O) C, 58.36; H, 6.58; N, 8.51. Found: C, 58.48; H, 6.68; N, 8.33.

20

**7-*tert*-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-3-*exo*-hydroxyl-7-azabicyclo[2.2.1]heptane:** To a stirred solution of 7-*tert*-butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one (40 mg, 0.12 mmol) in anhydrous THF (4 mL) at -78 °C under N<sub>2</sub> was added L-Selectride (1.0 M in THF, 160 μL, 0.16 mmol). The reaction mixture was slowly warmed to room temperature in 1 h. After this time, the solution was cooled to 0 °C and ethanol (0.5 mL) was added, followed by saturated aq. NH<sub>4</sub>Cl (0.5 mL) and then diluted with EtOAc (30 mL). The organic layer was separated and washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by chromatography with hexane-EtOAc (2:1) to give a syrup (37 mg, 92%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.21 (d, 1H, *J* = 2.1 Hz), 7.70 (d, 1H, *J* = 6.9 Hz), 7.28 (d, 1H, *J* = 8.4 Hz), 4.30 (d, 1H, *J* = 3.0 Hz), 4.19 (d, 1H, *J* = 5.1 Hz), 4.08 (t, 1H, *J* = 7.5 Hz), 3.04 (d, 1H, *J* = 7.5 Hz), 1.95-

30

1.70 (m, 3H), 1.58-1.50 (m, 2H), 1.48 (s, 9H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  156.09, 150.01, 149.95, 139.49, 133.14, 124.07, 80.69, 76.12, 63.16, 61.15, 51.92, 29.22, 28.49, 24.31. Anal. Calcd for  $(\text{C}_{16}\text{H}_{21}\text{ClN}_2\text{O}_3 \cdot 1/5\text{H}_2\text{O})$  C, 58.52; H, 6.57; N, 8.53. Found: C, 58.29; H, 6.27; N, 8.25.

5 **7-*tert*-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-3-*endo*-hydroxyl-7-**

**azabicyclo[2.2.1]heptane:** To a stirred solution of 7-*tert*-butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one (40 mg, 0.12 mmol) in THF (5 mL) was added  $\text{NaBH}_4$  (20 mg, 0.5 mmol) and water (200  $\mu\text{L}$ ) and the reaction mixture was stirred at room temperature for 1 h. After that water (5 mL) was added and neutralized to pH 7.0 with 1 M  
10 aq. HCl. (0.5 mL). The mixture was extracted with EtOAc ( $3 \times 10$  mL). The combined organic layer was washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by chromatography with hexane-EtOAc (2:1) to give a syrup (29 mg, 72%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.21 (d, 1H,  $J = 2.4$  Hz), 7.66 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.25 (d, 1H,  $J = 8.4$  Hz), 4.27 (t, 1H,  $J = 3.9$  Hz), 4.15-4.08 (m, 2H), 3.47 (d, 1H,  $J = 4.5$  Hz), 2.43 (d, 1H,  $J = 3.6$  Hz), 2.30-2.20 (m, 1H), 1.93-1.78 (m, 1H), 1.75-1.65 (m, 2H), 1.44 (s, 9H).  $^{13}\text{C}$  NMR  
15 ( $\text{CDCl}_3$ )  $\delta$  155.61, 149.65, 148.52, 138.89, 137.47, 124.55, 80.57, 80.14, 63.10, 60.44, 54.20, 30.39, 28.45, 20.47. Anal. Calcd for  $(\text{C}_{16}\text{H}_{21}\text{ClN}_2\text{O}_3 \cdot 1/10\text{H}_2\text{O})$  C, 58.84; H, 6.54; N, 8.58. Found: C, 58.58; H, 6.28; N, 8.42.

20 **7-*tert*-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-5-*exo*-fluoro-7-**

**azabicyclo[2.2.1]heptane:** To a stirred solution of 7-*tert*-butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-5-*endo*-hydroxyl-7-azabicyclo[2.2.1]heptane (42 mg, 0.13 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (3 mL) at  $-78^\circ\text{C}$  under  $\text{N}_2$  was slowly added diethylaminosulfur trifluoride (66  $\mu\text{L}$ , 0.5 mmol). The reaction mixture was stirred at  $-78^\circ\text{C}$  for 1 h, and then warmed slowly to room  
25 temperature. After that the reaction mixture was quenched by adding saturated aqueous  $\text{NaHCO}_3$ , and diluted with EtOAc. The organic layer was washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by chromatography with hexane-EtOAc (5:1) to give the product (35 mg, 87%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.29 (d, 1H,  $J = 2.4$  Hz), 7.61 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.27 (d, 1H,  $J = 8.4$  Hz), 5.14 (d, 1H,  $J = 57.3$  Hz), 4.53  
30 (s, 1H), 4.16 (s, 1H), 3.06 (dd, 1H,  $J = 9.3, 5.1$  Hz), 2.67 (ddd, 1H,  $J = 13.2, 9.3, 2.4$  Hz), 2.35 (m, 1H), 1.80 (m, 1H), 1.62 (ddd, 1H,  $J = 24.9, 13.8, 2.1$  Hz), 1.42 (s, 9H).  $^{13}\text{C}$  NMR

2.35 (m, 1H), 1.80 (m, 1H), 1.62 (ddd, 1H,  $J = 24.9, 13.8, 2.1$  Hz), 1.42 (s, 9H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  154.59, 149.87, 148.92, 139.63, 137.45, 124.40, 90.14 (d,  $J = 191$  Hz), 80.97, 62.24, 58.32, 44.59, 38.10, 31.77, 28.43.  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ )  $\delta$  -114 (d,  $J = 191$  Hz).

5 **7-tert-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-6-*exo*-fluoro-7-azabicyclo[2.2.1]heptane:** Yield, 83%.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.31 (d, 1H,  $J = 2.4$  Hz), 7.62 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.27 (d, 1H,  $J = 8.4$  Hz), 5.12 (d, 1H,  $J = 57$  Hz), 4.37 (s, 1H), 4.32 (s, 1H), 3.62 (dd, 1H,  $J = 9.0, 5.1$  Hz), 2.30 (m, 1H), 2.19 (dd, 1H,  $J = 12.3, 9.0$  Hz), 1.95 (m, 1H), 1.53 (ddd, 1H,  $J = 25.2, 13.8, 2.4$  Hz), 1.41 (s, 9H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  154.59, 149.87, 149.25, 138.99, 137.93, 124.35, 90.06 (d,  $J = 194$  Hz), 80.97, 63.75, 56.85, 39.78, 36.54, 35.95, 28.41.  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ )  $\delta$  -115 (d,  $J = 293$  Hz).

**2-*endo*-(2-Chloro-5-pyridyl)-3-*exo*-hydroxyl-7-azabicyclo[2.2.1]heptane.**

**General procedure for removal of Boc group:** To a solution of 7-tert-butoxycarbonyl-2-*endo*-(2-chloro-5-pyridyl)-3-*exo*-hydroxyl-7-azabicyclo[2.2.1]heptane (90 mg, 0.28 mmol) in  $\text{CH}_2\text{Cl}_2$  (6 mL) under  $\text{N}_2$  was added trifluoroacetic acid (500  $\mu\text{L}$ ). The reaction mixture was stirred at room temperature for 3 h and then rendered basic with saturated aq.  $\text{Na}_2\text{CO}_3$ . The mixture was diluted with EtOAc (100 mL) and the organic phase was washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by chromatography with  $\text{CH}_2\text{Cl}_2$ -MeOH (2:1) to give the product (58 mg, 94%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.23 (d, 1H,  $J = 2.4$  Hz), 7.45 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.29 (d, 1H,  $J = 8.4$  Hz), 4.00 (d, 1H,  $J = 3.0$  Hz), 4.78 (t, 1H,  $J = 4.5$  Hz), 3.57 (d, 1H,  $J = 5.7$  Hz), 2.99 (s, 1H), 2.35 (br s, 2H), 1.76-1.62 (m, 1H), 1.46-1.15 (m, 3H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  149.78, 149.37, 138.42, 134.08, 124.17, 78.88, 64.78, 60.38, 57.73, 25.43, 23.12. Anal. Calcd for  $(\text{C}_{11}\text{H}_{13}\text{ClN}_2\text{O} \cdot 1/4\text{HCl})$  C, 56.51; H, 5.71; N, 11.98. Found: C, 56.86; H, 5.31; N, 11.64.

**2-*endo*-(2-Chloro-5-pyridyl)-3-*endo*-hydroxyl-7-azabicyclo[2.2.1]heptane:** Yield, 95%.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.23 (d, 1H,  $J = 2.4$  Hz), 7.66 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.26 (d, 1H,  $J = 8.4$  Hz), 4.46 (dd, 1H,  $J = 9.0, 3.9$  Hz), 3.75 (s, 1H), 3.64 (s, 1H), 3.18 (dd, 1H,  $J = 8.4, 3.9$  Hz), 2.49 (br s, 2H), 2.20 (m, 1H), 1.69 (m, 1H), 1.56-1.38 (m, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$

151.91, 149.57, 141.75, 132.10, 123.46, 70.86, 62.54, 61.88, 47.54, 24.02, 21.76. Anal. Calcd for (C<sub>11</sub>H<sub>13</sub>ClN<sub>2</sub>O·1/3H<sub>2</sub>O) C, 57.27; H, 5.97; N, 12.14. Found: C, 56.99; H, 5.89; N, 11.74.

- 5 **2-*exo*-(2-Chloro-5-pyridyl)-3-*exo*-hydroxyl-7-azabicyclo[2.2.1]heptane:** Yield, 90%. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.25 (d, 1H, *J* = 2.4 Hz), 7.70 (dd, 1H, *J* = 8.1, 2.4 Hz), 7.26 (d, 1H, *J* = 8.1 Hz), 3.98 (d, 1H, *J* = 6.9 Hz), 3.67 (s, 1H), 3.59 (d, 1H, *J* = 5.1 Hz), 2.90 (d, 1H, *J* = 6.9 Hz), 2.06 (br s, 2H), 1.71-1.62 (m, 1H), 1.58-1.50 (m, 2H), 1.48-1.38 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 150.13, 149.53, 139.47, 134.31, 123.90, 76.40, 63.02, 61.53, 51.48, 31.30, 25.08.
- 10 Anal. Calcd for (C<sub>11</sub>H<sub>13</sub>ClN<sub>2</sub>O·1/2H<sub>2</sub>O) C, 56.53; H, 6.04; N, 11.99. Found: C, 56.92; H, 5.99; N, 11.69.

- 2-*exo*-(2-Chloro-5-pyridyl)-3-*endo*-hydroxyl-7-azabicyclo[2.2.1]heptane:** Yield, 93%. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.29 (d, 1H, *J* = 2.4 Hz), 7.84 (dd, 1H, *J* = 8.4, 2.4 Hz), 7.24 (d, 1H, *J* = 8.4 Hz), 4.08 (td, 1H, *J* = 4.2, 1.2 Hz), 3.68 (t, 1H, *J* = 4.5 Hz), 3.54 (d, 1H, *J* = 4.5 Hz), 2.32 (br s, 2H), 2.29 (d, 1H, *J* = 3.9 Hz), 2.24 (ddd, 1H, *J* = 12.6, 8.7, 5.7 Hz), 1.74 (m, 1H), 1.65 (tt, 1H, *J* = 12.0, 4.8 Hz), 1.50 (tt, 1H, *J* = 12.0, 4.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 149.42, 148.78, 139.72, 137.95, 124.30, 81.16, 64.25, 60.92, 53.54, 32.46, 22.13. Anal. Calcd for (C<sub>11</sub>H<sub>13</sub>ClN<sub>2</sub>O·1/2H<sub>2</sub>O) C, 56.53; H, 6.04; N, 11.99. Found: C, 56.48; H, 5.70; N, 11.73.

20


- 2-*exo*-(2-Chloro-5-pyridyl)-5-*exo*-fluoro-7-azabicyclo[2.2.1]heptane:** Yield, 87%. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.32 (d, 1H, *J* = 2.7 Hz), 7.73 (dd, 1H, *J* = 8.4, 2.7 Hz), 7.26 (d, 1H, *J* = 8.4 Hz), 5.08 (dddd, 1H, *J* = 57.6, 7.2, 4.8, 2.4 Hz), 3.88 (t, 1H, *J* = 4.8 Hz), 3.50 (d, 1H, *J* = 5.1 Hz), 2.99 (dd, 1H, *J* = 9.3, 5.1 Hz), 2.61 (ddd, 1H, *J* = 12.9, 9.0, 2.4 Hz), 2.11 (m, 1H), 1.65 (br s, 1H), 1.61 (dd, 1H, *J* = 13.5, 5.7 Hz), 1.55 (ddd, 1H, *J* = 24.9, 13.8, 2.4 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 149.52, 148.95, 140.78, 137.89, 124.26, 92.69 (d, *J* = 189 Hz), 63.13 (d, *J* = 3 Hz), 59.08 (d, *J* = 20 Hz), 44.36, 39.25 (d, *J* = 24 Hz), 32.05 (d, *J* = 8 Hz). <sup>19</sup>F NMR (CDCl<sub>3</sub>) δ -113 (dt, *J* = 58, 21 Hz). Anal. Calcd for (C<sub>11</sub>H<sub>12</sub>ClFN<sub>2</sub>·0.5H<sub>2</sub>O) C, 57.15; H, 5.45; N, 12.12. Found: C, 57.14; H, 5.54; N, 11.85.

30



**2-*exo*-(2-Chloro-5-pyridyl)-6-*exo*-fluoro-7-azabicyclo[2.2.1]heptane:** Yield, 92%.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.35 (d, 1H,  $J = 2.4$  Hz), 7.74 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.26 (d, 1H,  $J = 8.4$  Hz), 5.06 (dddd, 1H,  $J = 58, 9.9, 4.8, 2.7$  Hz), 3.76 (t, 1H,  $J = 4.8$  Hz), 3.64 (d, 1H,  $J = 4.5$  Hz), 3.56 (dd, 1H,  $J = 9.0, 5.4$  Hz), 2.14 (dd, 1H,  $J = 12.6, 9.0$  Hz), 2.10 (m, 1H), 1.78 (m, 1H), 1.70 (br s, 1H), 1.46 (ddd, 1H,  $J = 25.2, 13.5, 2.7$  Hz).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  149.54, 149.25, 140.18, 138.30, 124.23, 92.59 (d,  $J = 191$  Hz), 65.30 (d,  $J = 19$  Hz), 57.32 (d,  $J = 3$  Hz), 40.10, 37.45 (d,  $J = 23$  Hz), 35.57 (d,  $J = 8$  Hz).  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ )  $\delta$  -115 (ddd,  $J = 58, 25, 15$  Hz). Anal. Calcd for ( $\text{C}_{11}\text{H}_{12}\text{ClFN}_2 \cdot 0.3\text{H}_2\text{O}$ ) C, 56.93; H, 5.47; N, 12.07. Found: C, 57.19; H, 5.56; N, 11.67.

10



15

HCO<sub>2</sub>H, DMF, 75 °C, 92%. (vi) a). HClO<sub>4</sub>; b). Boc<sub>2</sub>O, Et<sub>3</sub>N, THF, 77-83% for two steps. (vii) SmI<sub>2</sub>, THF-H<sub>2</sub>O. (viii) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, 93-97%.

**1-Bromo-2-*p*-tolylsulfonylacetylene:** To a stirred solution of trimethylsilyl *p*-tolylsulfonylacetylene (10 g, 40 mmol) in acetone (300 mL) was added silver nitrate (0.68 g, 4 mmol) followed by the addition of *N*-bromosuccinimide (7.6 g, 44 mmol) in one portion. The mixture was stirred at room temperature for 1 h. The resulting precipitate was filtered and washed with acetone. Silica gel (20 g) was added to the filtrate and the solvent was removed under reduced pressure. The residue was subjected to column chromatography with hexane/EtOAc (5:1) to afford the product as a light yellow solid (10 g, 96%). Mp. 99-101°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.87 (d, 2H, *J* = 7.8 Hz), 7.39 (d, 2H, *J* = 7.8 Hz), 2.47 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 146.19, 138.16, 130.34, 127.83, 78.14, 61.70, 21.97.

**7-*tert*-Butoxycarbonyl-2-bromo-3-(*p*-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-2,5-diene:** A mixture of Boc-pyrrole (6.43 g, 38.4 mmol), toluene (10 mL), and 1-bromo-2-*p*-tolylsulfonylacetylene (5 g, 19.2 mmol) was stirred at 90 °C under N<sub>2</sub> for 24 h. After cooled to room temperature, the reaction mixture was passed through a short silica gel column. The crude product was purified by chromatography with n-Hexane/EtOAc (5:1) to afford a light yellow syrup (5.8 g, 71%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.81 (d, 2H, *J* = 8.1 Hz), 7.36 (d, 2H, *J* = 8.1 Hz), 6.98 (s, 1H), 6.97 (br s, 1H), 5.38 (s, 1H), 5.17 (br s, 1H), 2.45 (s, 3H), 1.31 (s, 9H).

**7-*tert*-Butoxycarbonyl-2-oxo-3-(*p*-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-5-ene:**

To a stirred solution of 7-*tert*-butoxycarbonyl-2-bromo-3-(*p*-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-2,5-diene (5.7 g, 13.4 mmol) and triethylamine (9.5 mL, 67 mmol) in acetonitrile (35 mL) was added dropwise a solution of diethylamine (1.5 mL, 15 mmol) in acetonitrile (20 mL) under N<sub>2</sub>. The mixture was stirred at room temperature for 1.5 h. A 10% HCl (45 mL) solution was then added dropwise. The mixture was stirred for additional 4 h. Water (40 mL) was added and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL × 3). The combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The

residue was purified by chromatography with hexane-EtOAc (2:1) to give the product as a mixture (4.1 g, 84%). 2- $\alpha$  isomer:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.81 (d, 1H,  $J = 8.1$  Hz), 7.38 (d, 1H,  $J = 8.1$  Hz), 6.96 (dd, 1H,  $J = 6.0, 2.1$  Hz), 4.27 (ddt, 1H,  $J = 5.4, 2.7, 0.9$  Hz), 5.19 (s, 1H), 4.70 (s, 1H), 4.01 (d, 1H,  $J = 3.9$  Hz), 2.46 (s, 3H), 1.42 (s, 9H). 2- $\beta$  isomer:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.77 (d, 1H,  $J = 8.1$  Hz), 7.32 (d, 1H,  $J = 8.1$  Hz), 6.76 (d, 1H,  $J = 3.6$  Hz), 6.55 (s, 1H), 5.45 (s, 1H), 4.57 (s, 1H), 3.55 (s, 1H), 2.43 (s, 3H), 1.41 (s, 9H).

**7-*tert*-Butoxycarbonyl-2-oxo-7-azabicyclo[2.2.1]hept-5-ene:**

7-*tert*-Butoxycarbonyl-2-oxo-3-(*p*-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-5-ene (2.4 g, 6.6 mmol) in THF (20 mL) and MeOH (10 mL) was added to 140 mL of a solution of  $\text{SmI}_2$  (0.1 M in THF, 14 mmol) at  $-78^\circ\text{C}$  under  $\text{N}_2$ . The resultant brown mixture was stirred for 10 min at  $-78^\circ\text{C}$  and then warmed to room temperature. The reaction mixture was quenched by adding saturated aq.  $\text{K}_2\text{CO}_3$ , and filtered. The filtrate was concentrated in vacuo and the residue was dissolved in EtOAc (100 mL), washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by chromatography with n-hexane-EtOAc (5:1) to give a light yellow oil (1.31 g, 95%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.73 (dd, 1H,  $J = 5.4, 1.8$  Hz), 6.42 (d, 1H,  $J = 4.2$  Hz), 5.06 (s, 1H), 4.55 (s, 1H), 2.29 (dd, 1H,  $J = 15.9, 3.9$  Hz), 1.91 (d, 1H,  $J = 15.9$  Hz), 1.44 (s, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  205.48, 155.18, 143.10, 130.61, 81.56, 68.38, 60.20, 35.98, 28.29.

**Preparation of the 1,3-dioxolane from 7-*tert*-butoxycarbonyl-2-oxo-7-**

**azabicyclo[2.2.1]hept-5-ene:** A solution of 7-*tert*-Butoxycarbonyl-2-oxo-7-

azabicyclo[2.2.1]hept-5-ene (460 mg, 2.2 mmol), THF (2 mL), ethylene glycol (0.24 mL, 4.4 mmol), triethyl orthoformate (0.56 mL, 3.4 mmol) and PTSA (50 mg) was stirred at room temperature for 3 days. The reaction mixture was concentrated and the residue was purified by chromatography with hexane-EtOAc (5:1) to give the 1,3-dioxolane (355 mg, 64%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.60-6.30 (m, 2H), 4.73 (s, 1H), 4.35 (m, 1H), 4.10-3.85 (m, 4H), 2.19 (dd, 1H,  $J = 12.0, 3.9$  Hz), 1.55 (d, 1H,  $J = 12.0$  Hz), 1.42 (s, 9H).

**2-*exo*-(2-Chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-5-one and 2-*exo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-6-one:** To a stirred mixture of the above 1,3-dioxolane (330 mg, 1.31 mmol), 2-chloro-5-iodopyridine (0.85 g, 3.95 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (230 mg, 0.2 mmol) in DMF (3 mL) at room temperature under argon was added piperidine (0.45 mL, 4.6 mmol) and formic acid (0.15 mL, 3.95 mmol). The reaction mixture was stirred at 75 °C for 48 h. The solvent was removed in vacuo and the residue was dissolved in EtOAc (100 mL), washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The resulting residue was purified by chromatography with hexane-EtOAc (4:1) to give a syrup (445 mg, 92%).

The above syrup was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) and 70% HClO<sub>4</sub> (1 mL) was added. The reaction mixture was stirred at room temperature for 5 h. The solution was adjusted to pH = 7 with aq. NaHCO<sub>3</sub>. The mixture was extracted with EtOAc. The organic layers were combined, washed with brine, dried and concentrated. The residue was purified by chromatography with EtOAc. **2-*exo*-(2-Chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-5-one:** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.37 (d, 1H, *J* = 2.7 Hz), 7.87 (dd, 1H, *J* = 8.4, 2.7 Hz), 7.28 (d, 1H, *J* = 8.4 Hz), 3.87 (d, 1H, *J* = 5.4 Hz), 3.74 (d, 1H, *J* = 5.4 Hz), 3.00 (dd, 1H, *J* = 9.0, 4.8 Hz), 2.33 (dd, 1H, *J* = 18.0, 5.4 Hz), 2.24-2.15 (m, 2H), 1.90 (dt, 1H, *J* = 13.5, 5.4 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 214.38, 149.70, 148.86, 139.77, 137.89, 124.15, 63.82, 61.87, 46.23, 42.70, 34.18. **2-*exo*-(2-Chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-6-one:** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.37 (d, 1H, *J* = 2.4 Hz), 7.81 (dd, 1H, *J* = 8.4, 2.4 Hz), 7.27 (d, 1H, *J* = 8.4 Hz), 4.18 (t, 1H, *J* = 4.8 Hz), 3.53 (s, 1H), 3.07 (dd, 1H, *J* = 9.0, 5.1 Hz), 2.32 (dq, 1H, *J* = 18.0, 2.7 Hz), 2.23-2.12 (m, 2H), 2.00-1.91 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 213.42, 149.93, 148.85, 138.33, 137.89, 124.16, 70.12, 55.70, 45.38, 38.79, 38.44.

**7-*tert*-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-5-one:**

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.30 (d, 1H, *J* = 2.4 Hz), 7.65 (dd, 1H, *J* = 8.4, 2.4 Hz), 7.29 (d, 1H, *J* = 8.4 Hz), 4.51 (d, 1H, *J* = 5.1 Hz), 4.38 (d, 1H, *J* = 5.7 Hz), 3.11 (dd, 1H, *J* = 9.0, 5.1 Hz), 2.55 (dd, 1H, *J* = 17.7, 5.4 Hz), 2.31-2.03 (m, 3H), 1.44 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 208.72, 154.45, 149.98, 148.53, 138.24, 137.08, 124.29, 81.57, 63.64, 62.18, 44.62, 43.20, 34.28, 28.08.

**7-tert-Butoxycarbonyl-2-exo-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-6-one:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.29 (d, 1H,  $J = 2.4$  Hz), 7.61 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.27 (d, 1H,  $J = 8.4$  Hz), 4.76 (t, 1H,  $J = 4.8$  Hz), 4.20 (s, 1H), 3.17 (dd, 1H,  $J = 9.0, 5.1$  Hz), 2.52 (dq, 1H,  $J = 18.0, 2.4$  Hz), 2.23 (dd, 1H,  $J = 12.9, 9.0$  Hz), 2.15 (d, 1H,  $J = 18.0$  Hz), 2.07 (m, 1H),  
 5 1.41 (s, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  208.03, 154.34, 150.17, 148.59, 137.30, 136.88, 124.26, 81.53, 69.13, 56.41, 43.97, 39.84, 38.11, 28.08. MS  $m/z$  (%): 324 ( $[\text{M}+2]^+$ , 0.3), 322 ( $\text{M}^+$ , 0.8), 294 (12), 266 (38), 240 (31), 238 (95), 194 (53), 179 (33), 167 (55), 142 (34), 140 (100), 126 (28).

10 **General procedure for  $\text{SmI}_2$  reduction of the ketone:** 7-tert-Butoxycarbonyl-2-exo-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-5-one (32 mg, 0.1 mmol) in 1 mL of THF and 0.5 mL of water was added to a solution of  $\text{SmI}_2$  (0.1 M in THF, 2 mL, 0.2 mmol) at room temperature under  $\text{N}_2$ . After 10 min 1 M HCl was added and the mixture was diluted with EtOAc (20 mL). The organic phase was isolated and washed with brine, dried over  $\text{Na}_2\text{SO}_4$ ,  
 15 and concentrated. The residue was purified by chromatography with hexane-EtOAc (2:1 to 1:1) to give the two alcohols.

**7-tert-Butoxycarbonyl-2-exo-(2-chloro-5-pyridyl)-5-endo-hydroxyl-7-azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.27 (d, 1H,  $J = 2.1$  Hz), 7.62 (dd, 1H,  $J = 8.4, 2.1$  Hz), 7.26 (d, 1H,  $J = 8.4$  Hz), 4.43 (s, 1H), 4.31 (s, 1H), 4.10 (s, 1H), 3.03 (dd, 1H,  $J = 9.0, 4.5$  Hz), 2.79 (dd, 1H,  $J = 12.6, 9.0$  Hz), 2.52 (br s, 1H), 2.33 (s, 1H), 1.70 (dtd, 1H,  $J = 12.9, 4.8, 1.2$  Hz), 1.42 (s, 9H), 1.32 (dd, 1H,  $J = 12.9, 3.0$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  155.00, 149.56, 148.86, 140.20, 137.58, 124.34, 80.53, 70.16, 63.07, 59.82, 45.17, 40.01, 31.19, 28.45. MS  $m/z$  (%): 326 ( $[\text{M}+2]^+$ , 0.1), 324 ( $\text{M}^+$ , 0.3), 268 (2), 226 (9), 224 (28), 179  
 25 (12), 142 (33), 140 (100).

**7-tert-Butoxycarbonyl-2-exo-(2-chloro-5-pyridyl)-5-exo-hydroxyl-7-azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.24 (d, 1H,  $J = 2.7$  Hz), 7.60 (dd, 1H,  $J = 8.4, 2.7$  Hz), 7.25 (d, 1H,  $J = 8.4$  Hz), 4.35 (d, 1H,  $J = 4.2$  Hz), 4.24 (d, 1H,  $J = 4.8$  Hz),  
 30 4.13 (tt?, 1H,  $J = 4.5, 1.8$  Hz), 2.76 (dd, 1H,  $J = 8.7, 4.5$  Hz), 2.40 (br s, 1H), 2.04 (dd, 1H,  $J = 13.5, 6.9$  Hz), 1.90 (dd, 1H,  $J = 13.2, 8.7$  Hz), 1.80 (dt, 1H,  $J = 13.2, 4.8$  Hz), 1.71 (dd,

1H,  $J = 13.5, 3.9$  Hz), 1.44 (s, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  155.79, 149.50, 148.70, 139.28, 137.20, 124.08, 80.45, 74.62, 62.66, 61.11, 43.78, 41.94, 34.37, 28.27.

**7-*tert*-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-6-*endo*-hydroxyl-7-**

5 **azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.30 (d, 1H,  $J = 2.4$  Hz), 7.66 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.25 (d, 1H,  $J = 8.4$  Hz), 4.42 (s, 1H), 4.30 (s, 1H), 4.09 (s, 1H), 3.78 (dd, 1H,  $J = 9.0, 5.4$  Hz), 2.51 (br s, 1H), 2.29 (s, 1H), 2.14 (dd, 1H,  $J = 12.3, 9.0$  Hz), 1.86 (m, 1H), 1.42 (s, 9H), 1.23 (dd, 1H,  $J = 12.9, 3.0$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  154.79, 149.06, 148.73, 139.97, 137.88, 124.20, 80.25, 69.97, 65.78 and 65.22 (br), 57.52 and 56.65 (br), 40.89 and  
10 40.00 (br), 37.90, 35.49 (br), 28.19.

**7-*tert*-Butoxycarbonyl-2-*exo*-(2-chloro-5-pyridyl)-6-*exo*-hydroxyl-7-**

**azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.26 (d, 1H,  $J = 2.4$  Hz), 7.61 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.26 (d, 1H,  $J = 8.4$  Hz), 4.45 (t, 1H,  $J = 4.5$  Hz), 4.17-4.12 (m, 2H), 2.75 (dd, 1H,  $J = 9.0, 5.4$  Hz), 2.25 (br s, 1H), 1.96 (dd, 1H,  $J = 13.2, 6.6$  Hz), 1.88 (dd, 1H,  $J = 12.3, 9.0$  Hz), 1.76-1.63 (m, 2H), 1.44 (s, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  155.71, 149.56, 148.65, 138.85, 137.30, 124.21, 80.43, 74.77, 68.47, 55.30, 41.19, 40.01, 39.25, 28.27.

**General procedure for the removal of the Boc group:** To a solution of Boc protected  
20 starting material in  $\text{CH}_2\text{Cl}_2$  (1 mL) was added dropwise with stirring under  $\text{N}_2$  trifluoroacetic acid (100  $\mu\text{L}$ ). The reaction mixture was stirred at room temperature for 3 h and then rendered basic with saturated aq.  $\text{Na}_2\text{CO}_3$ . The mixture was diluted with EtOAc (20 mL) and the organic phase was washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by chromatography with  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  (2:1) to  
25 give the product.

**2-*exo*-(2-Chloro-5-pyridyl)-5-*endo*-hydroxyl-7-azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.31 (d, 1H,  $J = 2.4$  Hz), 7.72 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.25 (d, 1H,  $J = 8.4$  Hz), 4.35 (dtd, 1H,  $J = 10.2, 3.9, 1.2$  Hz), 3.68 (t, 1H,  $J = 4.5$  Hz), 3.48 (d, 1H,  $J = 5.1$  Hz), 2.97  
30 (dd, 1H,  $J = 9.0, 4.5$  Hz), 2.70 (dd, 1H,  $J = 12.6, 9.0$  Hz), 2.13 (ddd, 1H,  $J = 12.9, 9.9, 5.4$


Hz), 1.80 (br s, 2H), 1.55 (dtd, 1H,  $J = 12.6, 4.8, 1.2$  Hz), 1.24 (dd, 1H,  $J = 12.9, 3.3$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  149.34, 148.97, 141.05, 137.90, 124.21, 72.50, 63.75, 60.71, 45.04, 41.23, 31.74.

5 **2-*exo*-(2-Chloro-5-pyridyl)-5-*exo*-hydroxyl-7-azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.28 (d, 1H,  $J = 2.4$  Hz), 7.81 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.25 (d, 1H,  $J = 8.4$  Hz), 4.07 (dd, 1H,  $J = 6.3, 1.5$  Hz), 3.56 (d, 1H,  $J = 5.7$  Hz), 3.54 (d, 1H,  $J = 4.8$  Hz), 2.64 (dd, 1H,  $J = 9.0, 4.2$  Hz), 1.98 (dd, 1H,  $J = 13.5, 6.3$  Hz), 1.84 (br s, 2H), 1.75 (dd, 1H,  $J = 13.2, 9.0$  Hz), 1.61 (dt, 1H,  $J = 12.9, 4.8$  Hz), 1.42 (dd, 1H,  $J = 13.5, 4.8$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  149.46, 149.12, 140.54, 138.06, 124.19, 74.34, 63.63, 61.82, 43.61, 34.14.


**2-*exo*-(2-Chloro-5-pyridyl)-6-*endo*-hydroxyl-7-azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.34 (d, 1H,  $J = 2.7$  Hz), 7.74 (dd, 1H,  $J = 8.4, 2.7$  Hz), 7.25 (d, 1H,  $J = 8.4$  Hz), 4.34 (dt, 1H,  $J = 10.2, 4.5$  Hz), 3.71 (t, 1H,  $J = 5.4$  Hz), 3.69 (dd, 1H,  $J = 9.3, 5.4$  Hz), 3.44 (d, 1H,  $J = 4.8$  Hz), 2.11 (m, 1H), 2.10 (dd, 1H,  $J = 12.6, 9.3$  Hz), 1.72 (m, 1H), 1.68 (br s, 2H), 1.16 (dd, 1H,  $J = 12.6, 3.9$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  149.29, 149.00, 140.76, 138.07, 123.98, 72.59, 66.82, 57.67, 40.77, 39.18, 35.10.

**2-*exo*-(2-Chloro-5-pyridyl)-6-*exo*-hydroxyl-7-azabicyclo[2.2.1]heptane:**  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.28 (d, 1H,  $J = 2.4$  Hz), 7.78 (dd, 1H,  $J = 8.4, 2.4$  Hz), 7.25 (d, 1H,  $J = 8.4$  Hz), 4.08 (d, 1H,  $J = 5.7$  Hz), 3.79 (t, 1H,  $J = 4.5$  Hz), 3.35 (s, 1H), 2.57 (dd, 1H,  $J = 8.7, 5.7$  Hz), 1.92 (dd, 1H,  $J = 13.2, 6.3$  Hz), 1.79 (dd, 1H,  $J = 12.0, 8.7$  Hz), 1.72 (br s, 2H), 1.58-1.49 (m, 1H), 1.45-1.36 (m, 1H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  149.25, 148.72, 137.75, 124.12, 74.33, 69.78, 55.33, 42.43, 39.77, 39.09.

25



10



- 15 **7-*tert*-Butoxycarbonyl-7-azabicyclo[2.2.1]hept-2-ene:** A solution of 7-*tert*-butoxycarbonyl-2-(*p*-tolylsulfonyl)-7-azabicyclo[2.2.1]hept-2-ene (11.5 g, 33 mmol), benzene (125 mL), *n*-Bu<sub>3</sub>SnH (20 g, 68.7 mmol) and AIBN (300 mg) was refluxed under N<sub>2</sub> for 3 h and then cooled to room temperature, and concentrated. The residue was purified by chromatography with hexane/EtOAc (10:0 to 10:1) to give a colorless oil (15 g). The product was dissolved in THF (150 mL) and *n*Bu<sub>4</sub>NF (1 M solution in THF, 46 mL) was added. The mixture was refluxed for 24 h and cooled to room temperature, and
- 20



concentrated. The residue was by chromatography with hexane/ether (10:1) to give a colorless oil (4.4 g, 97%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.22 (s, 2H), 4.66 (s, 2H), 1.84 (m, 2H), 1.42 (s, 9H), 1.10 (d, 2H, *J* = 7.5).

5       **7-*tert*-Butoxycarbonyl-7-azabicyclo[2.2.1]heptan-2-one. Method A:** To a solution of 7-*tert*-butoxycarbonyl-7-azabicyclo[2.2.1]hept-2-ene (3 g, 15.4 mmol) in THF (150 mL) at -78 °C under nitrogen was added 40 mL (40 mmol) of 1 M borane-THF complex in THF. The reaction mixture was warmed slowly to room temperature and stirred overnight at room temperature. Then the reaction mixture was quenched by sequentially addition of water (10  
10 mL), aqueous NaOH (6 M, 10 mL), and hydrogen peroxide (30% w/w, 20 mL). The mixture was stirred at room temperature for 30 min. The solvent was removed under reduced pressure and the residue was partitioned between EtOAc (200 mL) and water (50 mL). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by chromatography with hexane/EtOAc (3:1) to give 7-*tert*-  
15 butoxycarbonyl-2-*exo*-7-azabicyclo[2.2.1]heptan-2-ol as a colorless oil (1.5 g, 46%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.22 (t, 1H, *J* = 4.5 Hz), 4.11 (d, 1H, *J* = 4.5 Hz), 3.87 (dd, 1H, *J* = 6.9, 1.8 Hz), 3.10 (br s, 1H), 1.81 (dd, 1H, *J* = 12.9, 6.9 Hz), 1.76-1.58 (m, 3H), 1.45 (s, 9H), 1.30-1.20 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 156.38, 79.53, 73.89, 62.83, 55.11, 41.82, 28.08, 28.00, 23.80.

20       To a stirred solution of the above alcohol (1.2 g, 5.6 mmol) in methylene chloride (100 mL) was added Dess-Martin periodinane (2.75 g, 6.5 mmol). The reaction mixture was stirred overnight at room temperature. After removal of the solvent *in vacuo*, the residue was passed through a short silica gel column to give 7-*tert*-butoxycarbonyl-7-azabicyclo[2.2.1]heptan-2-one (1.18 g, 99%).

25

**Method B:** A solution of 7-*tert*-butoxycarbonyl-2-*exo*-tosyl-7-azabicyclo[2.2.1]heptane (500 mg, 1.4 mmol) in THF (4 mL) and MeOH (2 mL) was added to 28 mL (2.8 mmol) of SmI<sub>2</sub> (0.1 M solution in THF) at -78 °C under N<sub>2</sub>. The resultant mixture was stirred for 10 min at -78 °C and then warmed to room temperature. The reaction mixture was quenched  
30 by adding saturated aq. K<sub>2</sub>CO<sub>3</sub>, and filtered. The filtrate was concentrated in *vacuo* and the residue was dissolved in EtOAc (50 mL), washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and

concentrated. The residue was purified by chromatography with hexane/EtOAc (5:1) to give 7-*tert*-butoxycarbonyl-7-azabicyclo[2.2.1]heptan-2-one (260 mg, 90%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  4.56 (t, 1H,  $J = 4.5$  Hz), 4.25 (d, 1H,  $J = 4.8$  Hz), 2.48 (dd, 1H,  $J = 17.1, 5.1$  Hz), 2.10-1.92 (m, 3H), 1.69-1.55 (m, 2H), 1.46 (s, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  209.41, 154.91, 80.65, 63.77, 55.90, 45.07, 28.04, 27.40, 24.26.

**2-Methoxy-4-methylpyridine:** To a stirred solution of 2-hydroxy-4-methylpyridine (10 g, 92 mmol) in chloroform (350 mL) was added at room temperature silver carbonate (34.2 g, 124 mmol) and iodomethane (130 g, 920 mmol). The reaction mixture was stirred in the dark for 48 h, and then filtered through Celite and washed with ether. The filtrate was concentrated below 20 °C, and the residue was purified by chromatography with pentane/ether (5:1) to afford 2-methoxy-4-methylpyridine as a colorless oil (8.0 g, 71%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.02 (d, 1H,  $J = 5.4$  Hz), 6.69 (d, 1H,  $J = 5.4$  Hz), 6.55 (s, 1H), 3.91 (s, 3H), 2.28 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  164.40, 149.72, 146.31, 118.21, 110.88, 53.17, 20.81. MS  $m/z$  (%): 123 ( $\text{M}^+$ , 76), 122 (100).

**2-Methoxy-6-methylpyridine:** Yield, 93%; colorless oil.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.44 (t, 1H,  $J = 7.8$  Hz), 6.71 (d, 1H,  $J = 7.8$  Hz), 6.53 (d, 1H,  $J = 7.8$  Hz), 3.91 (s, 3H), 2.45 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  163.60, 156.25, 138.68, 115.63, 107.03, 53.18, 24.14. MS  $m/z$  (%): 123 ( $\text{M}^+$ , 79), 122 (100).

**4-(2-Hydroxyethyl)-2-methoxypyridine:** To a stirred solution of 2-methoxy-4-methylpyridine (6 g, 49 mmol) in anhydrous THF (200 mL) at -78 °C under nitrogen was added dropwise 29.4 mL (73.5 mmol) of *n*-BuLi (2.5 M solution in hexanes). The mixture was stirred at -78 °C for 1 h, and then warmed slowly to 0 °C and stirred at 0 °C for 30 min. The mixture was re-cooled to -78 °C and paraformaldehyde (10 g) was added in one portion. The mixture was warmed slowly to room temperature and stirred at room temperature for 8 h. The reaction was quenched by addition of saturated aq.  $\text{NH}_4\text{Cl}$  and extracted with EtOAc (150 mL  $\times$  3). The combined organic layers were washed with brine, dried ( $\text{MgSO}_4$ ), and concentrated. The residue was purified by chromatography with

hexane/EtOAc (2:1) to afford 4-(2-hydroxyethyl)-2-methoxypyridine as a colorless oil (3.8 g, 51%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.06 (d, 1H, *J* = 5.1 Hz), 6.77 (d, 1H, *J* = 5.1 Hz), 6.62 (s, 1H), 3.92 (s, 3H), 3.87 (t, 2H, *J* = 6.6 Hz), 2.81 (t, 2H, *J* = 6.6 Hz), 1.98 (br s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 164.48, 150.63, 146.71, 117.76, 110.91, 62.43, 53.34, 38.30. MS *m/z* (%):  
5 153 (M<sup>+</sup>, 73), 152 (100), 123 (48).

**6-(2-Hydroxyethyl)-2-methoxypyridine:** Yield, 49%; colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.49 (dd, 1H, *J* = 8.4, 7.5 Hz), 6.72 (d, 1H, *J* = 7.5 Hz), 6.60 (d, 1H, *J* = 8.4 Hz), 4.46 (br s, 1H), 3.99 (t, 2H, *J* = 5.4 Hz), 3.88 (s, 3H), 2.92 (t, 2H, *J* = 5.4 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ  
10 163.27, 157.88, 138.98, 115.56, 108.21, 61.70, 53.02, 38.35. MS *m/z* (%): 153 (M<sup>+</sup>, 22), 152 (15), 136 (68), 123 (100).

**5-Bromo-4-(2-hydroxyethyl)-2-methoxypyridine:** Bromine (2.95 g, 18.4 mmol) was slowly added to a stirred solution of 4-(2-hydroxyethyl)-2-methoxypyridine (1.4 g, 9.2 mmol) in 15 mL of absolute ethanol at 0 °C, and the reaction mixture was stirred at this  
15 temperature for 30 min. The mixture was neutralized by the addition of 2 N aq. NaOH and extracted with EtOAc (50 mL × 3). The organic layers were combined and washed with 5% aq. NaHSO<sub>3</sub> and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by chromatography with hexane/EtOAc (4:1) to afford 5-bromo-4-(2-hydroxyethyl)-2-methoxypyridine (1.93 g, 91%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.14 (s, 1H), 6.68 (s, 1H), 3.86 (s, 3H),  
20 3.85 (t, 2H, *J* = 6.6 Hz), 3.13 (br s, 1H), 2.90 (t, 2H, *J* = 6.6 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 163.27, 149.24, 148.00, 114.41, 112.60, 60.56, 53.63, 38.34.

**5-Bromo-6-(2-hydroxyethyl)-2-methoxypyridine:** Yield, 88%. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ  
25 7.66 (d, 1H, *J* = 8.7 Hz), 6.53 (d, 1H, *J* = 8.7 Hz), 4.05 (t, 2H, *J* = 5.4 Hz), 3.90 (br s, 1H), 3.89 (s, 3H), 3.07 (t, 2H, *J* = 5.4 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.28, 155.41, 142.54, 111.90, 111.20, 60.61, 53.52, 37.71.

**5-Bromo-4-[2-(*tert*-butyldimethylsilyloxy)ethyl]-2-methoxypyridine:** A mixture of 5-bromo-4-(2-hydroxyethyl)-2-methoxypyridine (2.33 g, 10 mmol), DMF (15 mL), imidazole (2.18 g, 32 mmol), DMAP (250 mg, 2 mmol), and TBDMSCl (2.44 g, 16 mmol) was stirred overnight at room temperature under nitrogen. After that the reaction mixture was diluted with ethyl acetate (150 mL), washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by chromatography with hexane/CH<sub>2</sub>Cl<sub>2</sub>/ether (10:1:1) to afford 5-bromo-4-[2-(*tert*-butyldimethylsilyloxy)ethyl]-2-methoxypyridine as a colorless oil (3.40 g, 98%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.20 (s, 1H), 6.68 (s, 1H), 3.90 (s, 3H), 3.83 (t, 2H, *J* = 6.6 Hz), 2.89 (t, 2H, *J* = 6.6 Hz), 0.86 (s, 9H), -0.06 (s, 6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 163.37, 149.47, 148.04, 114.55, 113.10, 61.41, 53.60, 38.71, 25.81, 18.20, -5.49.

**3-Bromo-2-[2-(*tert*-butyldimethylsilyloxy)ethyl]-6-methoxypyridine:** Yield, 98%; colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.62 (d, 1H, *J* = 8.7 Hz), 6.48 (d, 1H, *J* = 8.7 Hz), 4.01 (t, 2H, *J* = 7.2 Hz), 3.90 (s, 3H), 3.11 (t, 2H, *J* = 7.2 Hz), 0.88 (s, 9H), 0.02 (s, 6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.38, 154.66, 142.20, 112.15, 109.93, 61.88, 53.50, 40.24, 25.89, 18.28, -5.37.

**7-*tert*-Butoxycarbonyl-2-*exo*-2-{4-[2-(*tert*-butyldimethylsilyloxy)ethyl]-2-methoxy-5-pyridinyl}-7-azabicyclo[2.2.1]heptan-2-ol:** To a stirred solution of 5-bromo-4-[2-(*tert*-butyldimethylsilyloxy)ethyl]-2-methoxypyridine (385 mg, 1.1 mmol) in anhydrous THF (5 mL) at -78 °C under nitrogen was added dropwise 490 μL (1.22 mmol) of *n*-butyl lithium (2.5 M solution in hexanes). The reaction mixture was stirred at -78 °C for 1.5 h. The ketone 7-*tert*-butoxycarbonyl-7-azabicyclo[2.2.1]heptan-2-one (230 mg, 1.1 mmol) in THF (4 mL) was added dropwise and the mixture was stirred at -78 °C for another 1 h. After that it was slowly warmed to room temperature over a period of 1 h and stirred at room temperature for 0.5 h. The reaction was quenched by adding saturated aqueous NH<sub>4</sub>Cl and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by chromatography with hexane/EtOAc (6:1) to afford 7-*tert*-butoxycarbonyl-2-*exo*-2-{4-[2-(*tert*-butyldimethylsilyloxy)ethyl]-2-methoxy-5-pyridinyl}-7-azabicyclo[2.2.1]heptan-2-ol as a colorless syrup (425 mg, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.32 (s, 1H), 6.61 (s, 1H), 4.66 (s, 1H), 4.60 (s, 1H), 4.23 (br s, 1H), 4.07-3.99 (m, 1H), 3.93 (s, 3H), 3.84 (td, 1H, *J* = 9.9,

3.9 Hz), 3.23 (ddd, 1H,  $J = 13.5, 9.9, 5.1$  Hz), 2.80 (dm, 1H,  $J = 13.5$  Hz), 2.60-2.48 (m, 1H), 2.32-2.18 (m, 1H), 1.85-1.60 (m, 4H), 1.45 (s, 9H), 0.74 (s, 9H), -0.08 (s, 3H), -0.13 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  163.39, 150.42, 143.89, 134.89, 111.59, 79.66, 64.85, 63.54, 58.10 and 57.10, 53.35, 48.73, 35.06, 29.68 and 29.09, 28.32, 25.64, 22.29 and 21.37, 18.21, -5.77, -5.92.

**7-*tert*-Butoxycarbonyl-2-*exo*-2-{2-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-6-methoxy-3-pyridinyl}-7-azabicyclo[2.2.1]heptan-2-ol:** Yield, 86%; colorless syrup.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.78 (d, 1H,  $J = 8.7$  Hz), 6.52 (d, 1H,  $J = 8.7$  Hz), 4.84 (s, 1H), 4.52 (br s, 1H), 4.20 (br s, 1H), 4.16-4.03 (m, 2H), 3.89 (s, 3H), 3.39 (m, 1H), 2.80 (br d, 1H,  $J = 12.9$  Hz), 2.54 (m, 1H), 2.27 (dd, 1H,  $J = 12.3, 5.7$  Hz), 1.86 (d, 1H,  $J = 12.3$  Hz), 1.84-1.62 (m, 3H), 1.44 (s, 9H), 0.71 (s, 9H), -0.12 (s, 3H), -0.17 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  162.24, 155.17, 136.03, 135.47, 106.74, 79.52, 78.08, 63.59, 63.34, 57.86 and 56.72, 53.19, 49.58 and 49.18, 38.04, 29.63 and 29.14, 28.32, 25.60, 22.25 and 21.45, 18.19, -5.83, -6.04; MS  $m/z$  (%): 479 ( $\text{M}^+$ , 4), 421 (6), 321 (8), 310 (11), 290 (10), 252 (18), 246 (11), 245 (28), 178 (100), 177 (41), 162 (23), 136 (33), 114 (88).

**7-*tert*-Butoxycarbonyl-2-{4-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-2-methoxy-5-pyridinyl}-7-azabicyclo[2.2.1]hept-2-ene:** To a stirred solution of 7-*tert*-butoxycarbonyl-2-*exo*-2-{4-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-2-methoxy-5-pyridinyl}-7-azabicyclo[2.2.1]heptan-2-ol (470 mg, 0.98 mmol), DMAP (40 mg, 0.33 mmol),  $\text{Et}_3\text{N}$  (800  $\mu\text{L}$ , 5.74 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (8 mL) at 0 °C under  $\text{N}_2$  was added dropwise methanesulfonyl chloride (270  $\mu\text{L}$ , 3.5 mmol). After stirring at 0 °C for 1 h, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction mixture was quenched by addition of saturated aq.  $\text{NaHCO}_3$ , and then diluted with EtOAc (60 mL). The organic layer was washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. The residue was purified by chromatography with hexane/EtOAc (10:1) to afford 7-*tert*-butoxycarbonyl-2-{4-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-2-methoxy-5-pyridinyl}-7-azabicyclo[2.2.1]hept-2-ene (380 mg, 84%) as a white solid, mp. 75-76 °C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.92 (s, 1H), 6.67 (s, 1H), 6.24 (s, 1H), 4.88 (d, 1H,  $J = 3.3$  Hz), 4.79 (br s, 1H), 3.92 (s, 3H), 3.87-3.60 (m, 2H), 3.00-2.80 (m, 2H), 2.06-1.91 (m, 2H), 1.44 (s, 9H), 1.35-

1.20 (m, 2H), 0.84 (s, 9H), -0.04 (s, 6H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  163.61, 155.19, 149.66, 145.71, 144.90 and 143.54, 132.57 and 131.47, 123.63, 111.48, 79.84, 63.20, 62.52, 60.82, 53.23, 35.90, 28.12, 25.72, 25.24, 24.40 and 23.56, 18.11, -5.61. MS  $m/z$  (%): 460 ( $\text{M}^+$ , 1), 347 (12), 319 (62), 275 (100), 201 (21). Anal. Calcd for ( $\text{C}_{25}\text{H}_{40}\text{N}_2\text{O}_4\text{Si}$ ) C, 65.18; H, 8.75; N, 6.08. Found: C, 65.17; H, 8.84; N, 6.01.

**7-*tert*-Butoxycarbonyl-2-{2-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-6-methoxy-3-pyridinyl}-7-azabicyclo[2.2.1]hept-2-ene:** Yield, 87%; syrup.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.37 (br s, 1H), 6.54 (d, 1H,  $J = 8.4$  Hz), 6.26 (s, 1H), 4.89 (d, 1H,  $J = 3.6$  Hz), 4.78 (br s, 1H), 4.09-4.04 (m, 2H), 3.90 (s, 3H), 3.06-2.85 (m, 2H), 2.05-1.87 (m, 2H), 1.44 (s, 9H), 1.35-1.18 (m, 2H), 0.80 (s, 9H), -0.07 (s, 6H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  162.34, 155.37 and 154.88, 145.10, 138.70, 135.24, 132.00 and 130.71, 122.57, 116.22, 107.62, 79.86, 63.54, 62.74, 60.99, 53.14, 38.09, 28.18, 25.78, 25.17, 24.49 and 23.72, 18.20, -5.53. Anal. Calcd for ( $\text{C}_{25}\text{H}_{40}\text{N}_2\text{O}_4\text{Si} \cdot 3/4\text{H}_2\text{O}$ ) C, 63.32; H, 8.82; N, 5.91. Found: C, 62.92; H, 8.30; N, 5.96.

15

**7-*tert*-Butoxycarbonyl-2-[4-(2-hydroxyethyl)-2-methoxy-5-pyridinyl]-7-azabicyclo[2.2.1]hept-2-ene:** To a stirred solution of 7-*tert*-butoxycarbonyl-2-{4-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-2-methoxy-5-pyridinyl}-7-azabicyclo[2.2.1]hept-2-ene (360 mg, 0.78 mmol) in anhydrous THF (8 mL) was added 1.56 mL (1.56 mmol) of 1 M tetrabutylammonium fluoride in THF. The reaction solution was stirred at room temperature for 6 h, and then poured into a mixture of water (10 mL) and EtOAc (60 mL). The organic layer was separated and washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. The residue was purified by chromatography with hexane/EtOAc (2:1) to afford 7-*tert*-butoxycarbonyl-2-[4-(2-hydroxyethyl)-2-methoxy-5-pyridinyl]-7-azabicyclo[2.2.1]hept-2-ene as a syrup (270 mg, 100%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.82 (s, 1H), 6.66 (s, 1H), 6.20 (s, 1H), 4.91 (s, 1H), 4.78 (s, 1H), 3.91 (s, 3H), 3.77 (br s, 2H), 3.20-2.85 (m, 2H), 2.40 (br s, 1H), 2.10-1.89 (m, 2H), 1.44 (s, 9H), 1.36-1.16 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  164.05, 156.36, 149.36, 145.98, 144.61, 132.12, 123.75, 111.27, 80.38, 62.92, 62.28, 61.45, 53.33, 36.88, 28.16, 25.83, 23.46. MS  $m/z$  (%): 346 ( $\text{M}^+$ , 1), 318 (8), 262 (100), 218 (12), 199 (21). Anal. Calcd for ( $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_4 \cdot 1/3\text{H}_2\text{O}$ ) C, 64.75; H, 7.63; N, 7.95. Found: C, 64.55; H, 7.29; N, 7.64.

30

**7-tert-Butoxycarbonyl-2-[2-(2-hydroxyethyl)-6-methoxy-3-pyridinyl]-7-**

**azabicyclo[2.2.1]hept-2-ene:** Yield, 100%; syrup.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.42 (d, 1H,  $J = 8.4$  Hz), 6.64 (d, 1H,  $J = 8.4$  Hz), 6.18 (s, 1H), 4.84 (s, 1H), 4.81 (s, 1H), 4.48 (br s, 1H), 4.10-3.95 (m, 2H), 3.92 (s, 3H), 3.11-2.92 (m, 2H), 2.08-1.92 (m, 2H), 1.44 (s, 9H), 1.34-1.18 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  162.34, 156.06, 139.07, 132.62, 131.42, 122.00, 108.38, 80.18, 63.23, 61.45, 53.48, 36.30, 28.20, 25.32 and 24.65 and 23.84. MS  $m/z$  (%): 346 ( $\text{M}^+$ , 1), 318 (26), 262 (100), 232 (61), 188 (24). Anal. Calcd for  $(\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_4 \cdot 1/2\text{H}_2\text{O})$  C, 64.21; H, 7.66; N, 7.88. Found: C, 64.55; H, 7.48; N, 7.84.

**7-tert-Butoxycarbonyl-2-[4-(2-bromoethyl)-2-methoxy-5-pyridinyl]-7-**

**azabicyclo[2.2.1]hept-2-ene:** To a stirred solution of 7-tert-butoxycarbonyl-2-[4-(2-hydroxyethyl)-2-methoxy-5-pyridinyl]-7-azabicyclo[2.2.1]hept-2-ene (390 mg, 1.13 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (20 mL) under  $\text{N}_2$  was added  $\text{CBr}_4$  (745 mg, 2.25 mmol). The mixture was stirred at room temperature for 10 min, and then a solution of  $\text{PPh}_3$  (590 mg, 2.25 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (5 mL) was slowly added. After that the reaction mixture was stirred at room temperature for 2 h and quenched by water, and then diluted with  $\text{CH}_2\text{Cl}_2$ . The organic layer was separated and washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. The residue was purified by chromatography with hexane/EtOAc (6:1) to afford 7-tert-butoxycarbonyl-2-[4-(2-bromoethyl)-2-methoxy-5-pyridinyl]-7-azabicyclo[2.2.1]hept-2-ene as a syrup (400 mg, 87%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.95 (br s, 1H), 6.66 (s, 1H), 6.23 (br s, 1H), 4.86 (d, 1H,  $J = 3.6$  Hz), 4.81 (br s, 1H), 3.94 (s, 3H), 3.59-3.46 (m, 2H), 3.42-3.12 (m, 2H), 2.09-1.92 (m, 2H), 1.45 (s, 9H), 1.36-1.20 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  163.83, 155.35, 148.55, 146.16, 144.63, 132.04, 123.16, 111.15, 80.16, 63.16, 61.35, 53.44, 35.97, 30.76, 28.20, 25.96 and 25.32, 24.55 and 23.62.

**7-tert-Butoxycarbonyl-2-[2-(2-bromoethyl)-6-methoxy-3-pyridinyl]-7-**

**azabicyclo[2.2.1]hept-2-ene:** Yield, 88%; syrup.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.42 (d, 1H,  $J = 8.4$  Hz), 6.62 (d, 1H,  $J = 8.4$  Hz), 6.20 (s, 1H), 4.85 (s, 1H), 4.81 (s, 1H), 3.93 (s, 3H), 3.88 (t, 2H,  $J = 7.2$  Hz), 3.43-3.25 (m, 2H), 2.08-1.92 (m, 2H), 1.45 (s, 9H), 1.36-1.21 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  162.50, 155.37, 153.47, 145.38, 138.80, 132.28 and 131.11, 122.07, 108.44, 80.13, 63.41, 61.25, 53.39, 37.90, 30.96, 28.23, 25.82 and 25.22, 24.55 and 23.82.

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number  
**WO 2005/000806 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/439**,  
31/4375, C07D 471/18, A61P 25/00

(74) Agents: **GORDON, Dana, M.** et al.; Patent Group, Foley  
Hoag LLP, Seaport World Trade Center West, 155 Seaport  
Boulevard, Boston, MA 02210-2600 (US).

(21) International Application Number:  
PCT/US2004/018340

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(22) International Filing Date: 9 June 2004 (09.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/477,468 10 June 2003 (10.06.2003) US

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**GEORGETOWN UNIVERSITY** [US/US]; 37th and O  
Streets, NW, Washington, DC 20057-1408 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KOZIKOWSKI,**  
**Alan, P.** [US/US]; 2128 N. Racine Avenue, Chicago, IL  
60614 (US). **MUSACHIO, John, L.** [US/US]; 6200 Moss-  
way, Baltimore, MD 21212 (US). **KELLAR, Kenneth,**  
**J.** [US/US]; 7109 Braeburn Place, Bethesda, MD 20817  
(US). **XIAO, Yingxian** [US/US]; 11713 Tifton Drive,  
Potomac, MD 20854 (US). **WEI, Zhi-Liang** [CN/US];  
449 W. 28th Place, 2nd Floor, Chicago, IL 60616-2552  
(US).

Published:

— with international search report

(88) Date of publication of the international search report:  
24 March 2005

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM**

(57) Abstract: One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichotillomania.

WO 2005/000806 A3



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/18340

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : A61K 31/439, 31/4375; C07D 471/18; A61P 25/00 US CL : 514/292; 546/81 According to International Patent Classification (IPC) or to both national classification and IPC																	
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/292; 546/81 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE																	
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>US 5,242,916 A (LIPPIELLO et al.) 07 September 1993 (07.09.1993), column 6, line 5.</td> <td>1-3, 64-105</td> </tr> <tr> <td>X</td> <td>US 6,235,734 B1 (O'NEILL) 22 May 2001 (22.05.2001), columns 3-5, especially column 5, lines 38-45.</td> <td>1, 2, 64-105</td> </tr> <tr> <td>X</td> <td>BOIDO et al. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. II Farmaco. March 2003, Vol. 58, pages 265-277, especially pages 268-269.</td> <td>1-5, 7-9, 64-105</td> </tr> <tr> <td>X</td> <td>NICOLOTTI et al. Cytisine derivatives a high affinity nAChR ligands: synthesis and comparative molecular field analysis. II Farmaco. May 2002, Vol. 57, pages 469-478, especially page 471, Table 1.</td> <td>1-4, 7, 64-105</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	US 5,242,916 A (LIPPIELLO et al.) 07 September 1993 (07.09.1993), column 6, line 5.	1-3, 64-105	X	US 6,235,734 B1 (O'NEILL) 22 May 2001 (22.05.2001), columns 3-5, especially column 5, lines 38-45.	1, 2, 64-105	X	BOIDO et al. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. II Farmaco. March 2003, Vol. 58, pages 265-277, especially pages 268-269.	1-5, 7-9, 64-105	X	NICOLOTTI et al. Cytisine derivatives a high affinity nAChR ligands: synthesis and comparative molecular field analysis. II Farmaco. May 2002, Vol. 57, pages 469-478, especially page 471, Table 1.	1-4, 7, 64-105
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.															
X	US 5,242,916 A (LIPPIELLO et al.) 07 September 1993 (07.09.1993), column 6, line 5.	1-3, 64-105															
X	US 6,235,734 B1 (O'NEILL) 22 May 2001 (22.05.2001), columns 3-5, especially column 5, lines 38-45.	1, 2, 64-105															
X	BOIDO et al. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. II Farmaco. March 2003, Vol. 58, pages 265-277, especially pages 268-269.	1-5, 7-9, 64-105															
X	NICOLOTTI et al. Cytisine derivatives a high affinity nAChR ligands: synthesis and comparative molecular field analysis. II Farmaco. May 2002, Vol. 57, pages 469-478, especially page 471, Table 1.	1-4, 7, 64-105															
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																	
<table border="1"> <thead> <tr> <th>Special categories of cited documents:</th> <th></th> </tr> </thead> <tbody> <tr> <td>* "A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>* "E" earlier application or patent published on or after the international filing date</td> <td>* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>* "O" document referring to an oral disclosure, use, exhibition or other means</td> <td>* "&amp;" document member of the same patent family</td> </tr> <tr> <td>* "P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </tbody> </table>			Special categories of cited documents:		* "A" document defining the general state of the art which is not considered to be of particular relevance	* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	* "E" earlier application or patent published on or after the international filing date	* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	* "O" document referring to an oral disclosure, use, exhibition or other means	* "&" document member of the same patent family	* "P" document published prior to the international filing date but later than the priority date claimed				
Special categories of cited documents:																	
* "A" document defining the general state of the art which is not considered to be of particular relevance	* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																
* "E" earlier application or patent published on or after the international filing date	* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																
* "O" document referring to an oral disclosure, use, exhibition or other means	* "&" document member of the same patent family																
* "P" document published prior to the international filing date but later than the priority date claimed																	
Date of the actual completion of the international search 29 October 2004 (29.10.2004)		Date of mailing of the international search report <b>06 JAN 2005</b>															
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer <i>Christina Lawrence</i> Evelyn Huang Telephone No. (571) 272-1600															

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/18340

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-9, 64-105 in part

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US04/18340

### BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-9, 64-105 in part, drawn to a compound of formula I wherein  $a=1$ , and any two R1 does not form a fused ring, its composition and method of use.

Group II, claim(s) 1-9, 64-105 in part, drawn to a compound of formula I wherein  $a=1$ , and any two R1 form a fused ring, its composition and method of use.

Group III, claim(s) 1-9, 64-105 in part, drawn to a compound of formula I wherein  $a=2$ , and any two R1 does not form a fused ring, its composition and method of use.

Group IV, claim(s) 1-9, 64-105 in part, drawn to a compound of formula I wherein  $a=2$ , and any two R1 form a fused ring, its composition and method of use.

Group V, claim(s) 10-33, 38-40, 42-46, 64-105 in part, drawn to a compound of formula II wherein any two geminal or adjacent substituents does not form a monocyclic or bicyclic ring, its composition and method of use.

Group VI, claim(s) 34-37, 41 and claims 10-33, 38-40, 42-46, 64-105 in part, drawn to a compound of formula II wherein any two geminal or adjacent substituents form a monocyclic or bicyclic ring, its composition and method of use.

Group VII, claim(s) 47-63, and claims 64-105 in part, drawn to a compound of formula I wherein  $a=1$ , and any two R1 does not form a fused ring, its composition and method of use.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The piperidinyl containing tricyclic compound of Group I, the piperidinyl containing tetracyclic or pentacyclic compound of Group II, the azepinyl containing tricyclic compound of Group III, the azepinyl containing tetracyclic or pentacyclic compound of Group IV, the azabicyclic compound of Group V, the azatricyclic or azatetracyclic compound of Group VI, and the pyridinyl compound of Group VII would not have been of sufficient similarity to allow for a Markush grouping exhibiting unity, absent some teaching of equivalence in the prior art.

**THIS PAGE BLANK (USPTO)**